[{"title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"XE-ODN-GxesJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31710-7/abstract","googleCitationCount":606,"googleAuthor":""},{"title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","googleId":"jbBfhU99zq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309974","googleCitationCount":427,"googleAuthor":"M Yarchoan"},{"title":"4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)","googleId":"OovdHxUh4f4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34113-4/abstract","googleCitationCount":639,"googleAuthor":"F Cardoso"},{"title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"9BFapTr-f0EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31287-6/abstract","googleCitationCount":383,"googleAuthor":"F Cardoso"},{"title":"Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 …","googleId":"iH4n8WCRI_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341055","googleCitationCount":506,"googleAuthor":""},{"title":"Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"E_R-TgfQFuQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31692-8/abstract","googleCitationCount":346,"googleAuthor":""},{"title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"oIQVuQDeP1EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31711-9/abstract","googleCitationCount":237,"googleAuthor":"A Vogel"},{"title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","googleId":"rPeA_3if0MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348938","googleCitationCount":283,"googleAuthor":"L Derosa"},{"title":"ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …","googleId":"hWQqZLH2abIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311627","googleCitationCount":204,"googleAuthor":"N Colombo"},{"title":"Comprehensive analysis of the clinical immuno-oncology landscape","googleId":"JMxuRntBcUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350203","googleCitationCount":301,"googleAuthor":"J Tang"},{"title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","googleId":"-rKOmtHlwLEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931110X","googleCitationCount":214,"googleAuthor":"A Daud"},{"title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes …","googleId":"HVMLQS5nSUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454859","googleCitationCount":229,"googleAuthor":"L Horn"},{"title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","googleId":"nuUZaLcYH6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310750","googleCitationCount":203,"googleAuthor":""},{"title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast …","googleId":"wYsU2zHYLYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609786","googleCitationCount":151,"googleAuthor":"S Loibl"},{"title":"CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced …","googleId":"9HCRc53DNvAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603893","googleCitationCount":174,"googleAuthor":"T Yau"},{"title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","googleId":"I8ZTgQgo1xcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312840","googleCitationCount":175,"googleAuthor":"J Mazieres"},{"title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2 …","googleId":"KUsvv8xkoKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321052","googleCitationCount":240,"googleAuthor":"SM Stemmer"},{"title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro …","googleId":"xgZdBbeTMhwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341936","googleCitationCount":187,"googleAuthor":"KW Lee"},{"title":"Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"pNNlJJvhfpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31691-6/abstract","googleCitationCount":220,"googleAuthor":""},{"title":"Novel patterns of response under immunotherapy","googleId":"GAMzWoEnEhoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931083X","googleCitationCount":122,"googleAuthor":"Y Kanjanapan"},{"title":"Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"XRWSwiszWlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31151-2/abstract","googleCitationCount":156,"googleAuthor":""},{"title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …","googleId":"n1aDxA3wLe8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350173","googleCitationCount":198,"googleAuthor":"G Pentheroudakis"},{"title":"Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"VWEZuMEIBLoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31712-0/abstract","googleCitationCount":154,"googleAuthor":""},{"title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","googleId":"GCroUoe4INgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31698-9/abstract","googleCitationCount":220,"googleAuthor":"R Giusti"},{"title":"IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for …","googleId":"Jm2AXK-pY6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582072","googleCitationCount":132,"googleAuthor":"P Galle"},{"title":"Selective RET kinase inhibition for patients with RET-altered cancers","googleId":"BK7Pn-ZJLqwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341043","googleCitationCount":153,"googleAuthor":"V Subbiah"},{"title":"A decade of clinical development of PARP inhibitors in perspective","googleId":"y6ldpFWClDAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459851","googleCitationCount":112,"googleAuthor":"J Mateo"},{"title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","googleId":"6M7ygNDwgRwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312293","googleCitationCount":132,"googleAuthor":"M Silva"},{"title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …","googleId":"OhOda1_-_qUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312694","googleCitationCount":129,"googleAuthor":"C Luchini"},{"title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","googleId":"mCTvC-S32QoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50454-9/abstract","googleCitationCount":145,"googleAuthor":""},{"title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","googleId":"HCWSEYGxVdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312414","googleCitationCount":121,"googleAuthor":""},{"title":"Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors","googleId":"BtloFdMWIG8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316692","googleCitationCount":161,"googleAuthor":"CM Lovly"},{"title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"7JMTnEptucgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31690-4/abstract","googleCitationCount":136,"googleAuthor":""},{"title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","googleId":"CWHiydiOzTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345326","googleCitationCount":153,"googleAuthor":"MK McConechy"},{"title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","googleId":"LrlT1bUzII8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312402","googleCitationCount":129,"googleAuthor":"AB Schrock"},{"title":"ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up","googleId":"Z5_4ivDLP68J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934133X","googleCitationCount":120,"googleAuthor":"D Berney"},{"title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA …","googleId":"NaA7zsiFfF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311111","googleCitationCount":141,"googleAuthor":"ME Robson"},{"title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","googleId":"Z2g9gYxJEgoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341468","googleCitationCount":131,"googleAuthor":"AR Hansen"},{"title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","googleId":"yIEhPn-jRE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310762","googleCitationCount":161,"googleAuthor":"S Loi"},{"title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","googleId":"rxpHSpgEVSQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312025","googleCitationCount":107,"googleAuthor":"NJ Birkbak"},{"title":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer","googleId":"9X7u_Z26O6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945477X","googleCitationCount":138,"googleAuthor":"M Malvezzi"},{"title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","googleId":"rGRTXs2Y9gIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934997X","googleCitationCount":156,"googleAuthor":"A Betof"},{"title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GWGDRocMmTUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32563-1/abstract","googleCitationCount":88,"googleAuthor":"PA Ascierto"},{"title":"Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board","googleId":"whg1ImT-CS8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350720","googleCitationCount":138,"googleAuthor":""},{"title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage …","googleId":"CKBbpFfqB9MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345417","googleCitationCount":127,"googleAuthor":"MR Sydes"},{"title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","googleId":"8lloK8EpRN8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50436-7/abstract","googleCitationCount":117,"googleAuthor":"R Greil"},{"title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","googleId":"2orw7pHP3CsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320988","googleCitationCount":115,"googleAuthor":"M Bruzzone"},{"title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","googleId":"AaDdn2x1JM8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312372","googleCitationCount":110,"googleAuthor":"GJ Riely"},{"title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 …","googleId":"tw8SztNGAmoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459887","googleCitationCount":81,"googleAuthor":""},{"title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","googleId":"M20N-uY9ucwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345569","googleCitationCount":117,"googleAuthor":"S Gutiérrez-Enríquez"},{"title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","googleId":"TcW2JC9xwwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350069","googleCitationCount":137,"googleAuthor":"V Lemaire"},{"title":"European cancer mortality predictions for the year 2019 with focus on breast cancer","googleId":"JuabRO68Ai0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311561","googleCitationCount":103,"googleAuthor":"M Malvezzi"},{"title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","googleId":"fhrRhhCgghkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310816","googleCitationCount":105,"googleAuthor":"D Dong"},{"title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …","googleId":"jmz885CC1e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318848","googleCitationCount":105,"googleAuthor":"S Peters"},{"title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","googleId":"y3PaGTiJQdIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350379","googleCitationCount":129,"googleAuthor":"F Cardoso"},{"title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","googleId":"WqKlO74zAvMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454641","googleCitationCount":123,"googleAuthor":""},{"title":"Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer","googleId":"bME61RUdIk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354985","googleCitationCount":129,"googleAuthor":""},{"title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","googleId":"Rq1p5-uN4eMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31688-6/abstract","googleCitationCount":99,"googleAuthor":"M Dicato"},{"title":"Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials","googleId":"p_bZDQKIRaAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311597","googleCitationCount":88,"googleAuthor":"DH Lee"},{"title":"Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the …","googleId":"aJ-Ko0Ibtj4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325527","googleCitationCount":78,"googleAuthor":""},{"title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR …","googleId":"DYKqcjdUTUwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349014","googleCitationCount":116,"googleAuthor":"J Mazières"},{"title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic …","googleId":"NR80ytPApcMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341341","googleCitationCount":104,"googleAuthor":"TR Cottrell"},{"title":"Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer","googleId":"q2NPQJHIb-wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312311","googleCitationCount":84,"googleAuthor":"MH Hong"},{"title":"IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) …","googleId":"oiOwkryJ6fMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603595","googleCitationCount":78,"googleAuthor":""},{"title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","googleId":"f1jkyjFeOmsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316795","googleCitationCount":102,"googleAuthor":""},{"title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …","googleId":"m1ODQena_u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310464","googleCitationCount":70,"googleAuthor":"S Lu"},{"title":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results …","googleId":"tPKKWUyHOLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342462","googleCitationCount":85,"googleAuthor":"S Loibl"},{"title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","googleId":"AJ6vBhtPHH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609841","googleCitationCount":63,"googleAuthor":"JF Gainor"},{"title":"Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC","googleId":"zRwJzoFqamIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32762-0/abstract","googleCitationCount":86,"googleAuthor":"NA Rizvi"},{"title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","googleId":"kZCcStisSwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318861","googleCitationCount":80,"googleAuthor":"GV Long"},{"title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","googleId":"TfDayX7T_hMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459929","googleCitationCount":84,"googleAuthor":"C Marchiò"},{"title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"roYk1TxvdXIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31689-8/abstract","googleCitationCount":81,"googleAuthor":"I Ray-Coquard"},{"title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","googleId":"KZvArhuaafoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342413","googleCitationCount":89,"googleAuthor":"TG Kwon"},{"title":"Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or …","googleId":"MtuPwyffdCMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310361","googleCitationCount":70,"googleAuthor":""},{"title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"5eX2SfV5OHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341791","googleCitationCount":110,"googleAuthor":"J Mateo"},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"WgptB7ZVt1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603996","googleCitationCount":70,"googleAuthor":"J Mateo"},{"title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","googleId":"ZLv0BPO-6RcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342073","googleCitationCount":84,"googleAuthor":""},{"title":"How liquid biopsies can change clinical practice in oncology","googleId":"TtpBLXHkp8cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609725","googleCitationCount":55,"googleAuthor":"G Siravegna"},{"title":"Correction to:“Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"_3pKC04ni6sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31152-4/abstract","googleCitationCount":72,"googleAuthor":"A Vogel"},{"title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer …","googleId":"f__GGZDtafkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312785","googleCitationCount":102,"googleAuthor":"S Loibl"},{"title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","googleId":"5HT_3DNQlooJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50455-0/abstract","googleCitationCount":84,"googleAuthor":""},{"title":"ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an …","googleId":"jfU-RHVtjGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960387X","googleCitationCount":68,"googleAuthor":""},{"title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 …","googleId":"ubmiQDXRcIgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312104","googleCitationCount":81,"googleAuthor":"Y Fradet"},{"title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","googleId":"ZRjJkyqwv_8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350215","googleCitationCount":99,"googleAuthor":"F Scotté"},{"title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","googleId":"xG-NnAYhDXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454707","googleCitationCount":102,"googleAuthor":"Y Bareche"},{"title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","googleId":"eu1SFmu76QYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35043-4/abstract","googleCitationCount":96,"googleAuthor":"AG Marcelin"},{"title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331","googleId":"U2QG0fxaBlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32761-9/abstract","googleCitationCount":75,"googleAuthor":""},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial","googleId":"9zOYoaMAvCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50401-X/abstract","googleCitationCount":79,"googleAuthor":"F André"},{"title":"Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)","googleId":"vBdmkqm1QqQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50419-7/abstract","googleCitationCount":78,"googleAuthor":""},{"title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","googleId":"xnFuV0ZuYnkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354900","googleCitationCount":94,"googleAuthor":""},{"title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced …","googleId":"pO5kBYhk4FkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348926","googleCitationCount":83,"googleAuthor":""},{"title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","googleId":"sHKJXYmEJUUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312724","googleCitationCount":66,"googleAuthor":"HA Yu"},{"title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","googleId":"nNtHp7zSw7oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349919","googleCitationCount":94,"googleAuthor":"M Ilié"},{"title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"bcTa42E45d4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32555-2/abstract","googleCitationCount":84,"googleAuthor":"S Filetti"},{"title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","googleId":"SrujySyAX1QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310440","googleCitationCount":72,"googleAuthor":"N Steeghs"},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by …","googleId":"fCfp8uuhvtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310038","googleCitationCount":58,"googleAuthor":"G Pentheroudakis"},{"title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of …","googleId":"hjfkNGjS19sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454604","googleCitationCount":85,"googleAuthor":"JJ Yang"},{"title":"Immunological differences between primary and metastatic breast cancer","googleId":"YMCvlmhyiV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318782","googleCitationCount":73,"googleAuthor":"X Li"},{"title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GNA4kIAX048J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31693-X/abstract","googleCitationCount":63,"googleAuthor":"PL Zinzani"},{"title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","googleId":"n-RV3PkMrBYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31697-7/abstract","googleCitationCount":63,"googleAuthor":"NI Cherny"},{"title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","googleId":"4roaPHV5OkEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609671","googleCitationCount":41,"googleAuthor":"A Elkrief"},{"title":"Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis","googleId":"iPUKuO-jOJIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604369","googleCitationCount":58,"googleAuthor":""},{"title":"Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients","googleId":"hUIjPQsLEXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934983X","googleCitationCount":82,"googleAuthor":"V Bernard"},{"title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab …","googleId":"dpDeks1nvgEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50456-2/abstract","googleCitationCount":69,"googleAuthor":"F Cappuzzo"},{"title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","googleId":"TMTicSZFpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355115","googleCitationCount":112,"googleAuthor":"G Goss"},{"title":"Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast …","googleId":"j9n3rYkfiOUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349798","googleCitationCount":84,"googleAuthor":"M Robson"},{"title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","googleId":"EAJljg9-vMgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345570","googleCitationCount":66,"googleAuthor":"S Siena"},{"title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","googleId":"_9FpTDPFRjsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310294","googleCitationCount":68,"googleAuthor":"EA Blair"},{"title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","googleId":"Y_RnIY7LBNMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310245","googleCitationCount":57,"googleAuthor":"JM Loree"},{"title":"RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study","googleId":"z2Eb6009_PUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934534X","googleCitationCount":77,"googleAuthor":"JB Bachet"},{"title":"Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H …","googleId":"9MWA4VyBm4kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50410-0/abstract","googleCitationCount":64,"googleAuthor":"HJJ Lenz"},{"title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","googleId":"oWfOuyjvNCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349774","googleCitationCount":81,"googleAuthor":"IG Murillas"},{"title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","googleId":"SFv0W1jJUaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594042","googleCitationCount":51,"googleAuthor":"MG Fakih"},{"title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","googleId":"6srZZ6G8ZiAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310774","googleCitationCount":56,"googleAuthor":""},{"title":"Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib","googleId":"k4fb_JXeXpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311652","googleCitationCount":69,"googleAuthor":"AJ Schoenfeld"},{"title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","googleId":"HOtsu9gEikcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342036","googleCitationCount":54,"googleAuthor":"L Emmett"},{"title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","googleId":"4XrLOEF45I4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350033","googleCitationCount":75,"googleAuthor":"N Adra"},{"title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 …","googleId":"2auh0-fIwtYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595217","googleCitationCount":43,"googleAuthor":"H Gogas"},{"title":"Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","googleId":"zevF3PiDyUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931227X","googleCitationCount":54,"googleAuthor":"YJL Jansen"},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"vDaSB3-vMv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960390X","googleCitationCount":47,"googleAuthor":""},{"title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","googleId":"y851gSX83Z0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931035X","googleCitationCount":56,"googleAuthor":""},{"title":"Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer","googleId":"9j0uvrbDQh4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50438-0/abstract","googleCitationCount":59,"googleAuthor":""},{"title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant …","googleId":"vLCJ9MCArbMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325515","googleCitationCount":50,"googleAuthor":"G Bataillon"},{"title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","googleId":"P6jyX2doe-4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349178","googleCitationCount":59,"googleAuthor":"MR Mirza"},{"title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in …","googleId":"lSKLqWIqryIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311147","googleCitationCount":62,"googleAuthor":"WT Barry"},{"title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","googleId":"VH2wnWYIDlAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318964","googleCitationCount":52,"googleAuthor":""},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"2jn2ehTMEpUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50408-2/abstract","googleCitationCount":61,"googleAuthor":""},{"title":"Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"hqTJ9bBmyZUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60977-4/abstract","googleCitationCount":40,"googleAuthor":"F Carneiro"},{"title":"Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer","googleId":"f9GG1JvXz9wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454586","googleCitationCount":72,"googleAuthor":"N Feeney"},{"title":"Safety and dose modification for patients receiving niraparib","googleId":"iqtQSV85LXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341092","googleCitationCount":64,"googleAuthor":""},{"title":"A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma …","googleId":"LqvwrgRiaU0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354936","googleCitationCount":74,"googleAuthor":""},{"title":"Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting","googleId":"7RVfRil2YBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609737","googleCitationCount":37,"googleAuthor":""},{"title":"FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","googleId":"tzJq6OAr2FIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603911","googleCitationCount":45,"googleAuthor":"A Hollebecque"},{"title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"g7JkhZhsFgMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31696-5/abstract","googleCitationCount":53,"googleAuthor":"SH Bush"},{"title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo (radio) therapy: current …","googleId":"vmXWzOuDY_EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345661","googleCitationCount":56,"googleAuthor":"A Laviano"},{"title":"Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional …","googleId":"YkOYFko8N-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345338","googleCitationCount":66,"googleAuthor":""},{"title":"Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated …","googleId":"z6r8M_03wBAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50428-8/abstract","googleCitationCount":59,"googleAuthor":"BI Rini"},{"title":"Identifying patients with NTRK fusion cancer","googleId":"_zVnDmJ_F8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551183","googleCitationCount":46,"googleAuthor":"JF Hechtman"},{"title":"TRK inhibitors in TRK fusion-positive cancers","googleId":"pbNES49JFCwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551146","googleCitationCount":51,"googleAuthor":"A Drilon"},{"title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) …","googleId":"jkx2c8Pi3gsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312906","googleCitationCount":47,"googleAuthor":"T Sato"},{"title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","googleId":"n3ncIXWoiqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934904X","googleCitationCount":57,"googleAuthor":""},{"title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma","googleId":"7HpsXiZd5nEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350501","googleCitationCount":67,"googleAuthor":"RJ Lee"},{"title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for …","googleId":"Djtj1qIVatgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309858","googleCitationCount":50,"googleAuthor":"YP Chen"},{"title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal …","googleId":"oF-X3zRFY_wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603674","googleCitationCount":48,"googleAuthor":"S Chia"},{"title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and …","googleId":"nT3V-MJosoEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325539","googleCitationCount":33,"googleAuthor":"U Dafni"},{"title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","googleId":"c4_Mxz0sCQ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342061","googleCitationCount":57,"googleAuthor":"M Scheffler"},{"title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","googleId":"aH6AkxVOh1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342310","googleCitationCount":69,"googleAuthor":"AA Brandes"},{"title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after …","googleId":"4AdrvcxzRfAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310427","googleCitationCount":45,"googleAuthor":"SJ Luen"},{"title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","googleId":"VFnIN_ezYA0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341651","googleCitationCount":52,"googleAuthor":"C Massard"},{"title":"Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient …","googleId":"8UMUDp2Gh8IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341766","googleCitationCount":56,"googleAuthor":""},{"title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT)","googleId":"_gO3PTzClp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604023","googleCitationCount":43,"googleAuthor":"HG Kynaston"},{"title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro …","googleId":"wESk3ByKIIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603637","googleCitationCount":43,"googleAuthor":"R Dent"},{"title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","googleId":"YgTrH2tOFsIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420326016","googleCitationCount":45,"googleAuthor":"F Saad"},{"title":"Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase II KEYNOTE-158 study","googleId":"-BvgtB7RN94J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49087-X/abstract","googleCitationCount":52,"googleAuthor":"A Nagrial"},{"title":"Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution","googleId":"hFVONvIPuWwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355152","googleCitationCount":60,"googleAuthor":"S Venkatesan"},{"title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","googleId":"ITC6lEts3YAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931004X","googleCitationCount":44,"googleAuthor":""},{"title":"Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive …","googleId":"ySGaJ99_7m0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935495X","googleCitationCount":63,"googleAuthor":"SM Swain"},{"title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","googleId":"V0mTyQeYmDsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454513","googleCitationCount":64,"googleAuthor":"B Allard"},{"title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary …","googleId":"UmMY_-3_bgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454525","googleCitationCount":61,"googleAuthor":"H Takahashi"},{"title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","googleId":"X7U2Z5pwlL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311275","googleCitationCount":48,"googleAuthor":"R Alden"},{"title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","googleId":"XSoIvimC20kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459917","googleCitationCount":38,"googleAuthor":"B Lee"},{"title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the …","googleId":"bTEH5zyfKmEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604370","googleCitationCount":37,"googleAuthor":"RS Herbst"},{"title":"Long-course preoperative chemoradiation versus 5× 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results …","googleId":"-ztpBsjY5VQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312967","googleCitationCount":48,"googleAuthor":"W Michalski"},{"title":"Overview of current systemic management of EGFR-mutant NSCLC","googleId":"vFBC2Khe6MkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316680","googleCitationCount":58,"googleAuthor":"HH Loong"},{"title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","googleId":"zr4CoiyuQnAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310403","googleCitationCount":40,"googleAuthor":"RS Herbst"},{"title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","googleId":"iWz5eFiC5KIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312323","googleCitationCount":45,"googleAuthor":"JY Blay"},{"title":"Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc …","googleId":"0jR1BCf407QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603698","googleCitationCount":46,"googleAuthor":"S Loi"},{"title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas …","googleId":"scNCVpsFdAAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325904","googleCitationCount":31,"googleAuthor":"V Makker"},{"title":"The European society for medical oncology (ESMO) precision medicine glossary","googleId":"16uKHIZmFr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350112","googleCitationCount":61,"googleAuthor":"LL Siu"},{"title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural …","googleId":"haiUYizilZ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604515","googleCitationCount":37,"googleAuthor":""},{"title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular …","googleId":"x5G1gAdb-PgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318885","googleCitationCount":54,"googleAuthor":"CK Lee"},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and …","googleId":"odR8Vk1w7u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604382","googleCitationCount":34,"googleAuthor":""},{"title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","googleId":"HuF1PmDnk7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310397","googleCitationCount":37,"googleAuthor":"A Bardelli"},{"title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind …","googleId":"iVoGQe7utRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354912","googleCitationCount":57,"googleAuthor":""},{"title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with …","googleId":"nd2kB4tfcM4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50406-9/abstract","googleCitationCount":53,"googleAuthor":"J Brody"},{"title":"Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment …","googleId":"WAIpjOgnfGAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459954","googleCitationCount":47,"googleAuthor":"J Taieb"},{"title":"Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after …","googleId":"46IxcFkiSocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30259-5/abstract","googleCitationCount":47,"googleAuthor":"TK Owonikoko"},{"title":"JAVELIN renal 101: a randomized, Phase III study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","googleId":"7ycuXzG_e7YJ","googleLink":"https://researchers.mq.edu.au/files/117842959/Publisher_version_open_access_.pdf","googleCitationCount":48,"googleAuthor":"K Penkov"},{"title":"Corrections to “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"ya4axIpRsIQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31702-8/abstract","googleCitationCount":55,"googleAuthor":"S Mahner"},{"title":"Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis","googleId":"hQu2ROH9aHQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604011","googleCitationCount":34,"googleAuthor":""},{"title":"Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information","googleId":"BxJyYr852YUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454689","googleCitationCount":55,"googleAuthor":"S Kim"},{"title":"Optimizing panel-based tumor mutational burden (TMB) measurement","googleId":"S1HxzZuQ0lgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459930","googleCitationCount":47,"googleAuthor":"J Budczies"},{"title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","googleId":"V7m10H-CD6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454628","googleCitationCount":59,"googleAuthor":""},{"title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","googleId":"eziLk_KxKjYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603686","googleCitationCount":37,"googleAuthor":"H Wildiers"},{"title":"IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs …","googleId":"s2ZbG56JeBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604072","googleCitationCount":35,"googleAuthor":"ID Davis"},{"title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","googleId":"DsYea6thfiUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311676","googleCitationCount":42,"googleAuthor":""},{"title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a …","googleId":"Dtv_9UGKk2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311184","googleCitationCount":42,"googleAuthor":"O Chinot"},{"title":"Fluoropyrimidine (FP)+ bevacizumab (BEV)+ atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL–a …","googleId":"CnozItgixTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50411-2/abstract","googleCitationCount":44,"googleAuthor":"A Grothey"},{"title":"Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic …","googleId":"_TruGkshOrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342334","googleCitationCount":44,"googleAuthor":"F Diehl"},{"title":"Crizotinib in c-MET-or ROS1-positive NSCLC: results of the AcSé phase II trial","googleId":"sqRXiDd8Py0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325606","googleCitationCount":42,"googleAuthor":"J Mazières"},{"title":"KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","googleId":"9VGjLlghH7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603704","googleCitationCount":33,"googleAuthor":""},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"08Pe7nwlSfEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48876-5/abstract","googleCitationCount":43,"googleAuthor":"UN Lassen"},{"title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","googleId":"yltm_eoRTw4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312396","googleCitationCount":41,"googleAuthor":""},{"title":"Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate …","googleId":"IQkfwHD4KNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590627","googleCitationCount":32,"googleAuthor":"D Campbell"},{"title":"First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma","googleId":"McdKD_h4194J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590329","googleCitationCount":42,"googleAuthor":"YY Janjigian"},{"title":"Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian …","googleId":"g34MC1v7YkUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604138","googleCitationCount":33,"googleAuthor":"IL Ray-Coquard"},{"title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of …","googleId":"VEewJf0Hu6kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312827","googleCitationCount":33,"googleAuthor":""},{"title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","googleId":"1Gdv-h0Gr3gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341407","googleCitationCount":50,"googleAuthor":""},{"title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone …","googleId":"q-aW8DuuEI0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341705","googleCitationCount":47,"googleAuthor":""},{"title":"Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"5s9MQ2NMZO4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50458-6/abstract","googleCitationCount":42,"googleAuthor":"V Velcheti"},{"title":"Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer","googleId":"cJDlrTiTRyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454719","googleCitationCount":51,"googleAuthor":"N Priedigkeit"},{"title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA …","googleId":"yhogiUBXn4kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354997","googleCitationCount":48,"googleAuthor":""},{"title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the …","googleId":"0MebEzG64wIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321015","googleCitationCount":47,"googleAuthor":"C Cremolini"},{"title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","googleId":"3GpLyzqtnMoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345521","googleCitationCount":42,"googleAuthor":"JL Perez-Gracia"},{"title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","googleId":"gFl3-e4UZEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341754","googleCitationCount":41,"googleAuthor":""},{"title":"Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative …","googleId":"Tmzq_-ul8E0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341328","googleCitationCount":43,"googleAuthor":"L Malorni"},{"title":"A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results","googleId":"7mOFh48MmssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589633","googleCitationCount":35,"googleAuthor":"J Llovet"},{"title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More …","googleId":"zmzE8yWnucEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325898","googleCitationCount":25,"googleAuthor":"JMS Bartlett"},{"title":"CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC","googleId":"9vGOynXF3HQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596880","googleCitationCount":32,"googleAuthor":""},{"title":"Efficacy of PI3K inhibitors in advanced breast cancer","googleId":"fpx7lM_LjGEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034374X","googleCitationCount":35,"googleAuthor":"F Andre"},{"title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","googleId":"cArXuAfWad4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342358","googleCitationCount":38,"googleAuthor":"P Cottu"},{"title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","googleId":"wjQPzV-QDo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316710","googleCitationCount":49,"googleAuthor":"L Friboulet"},{"title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast …","googleId":"39qHxHyYTlMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341225","googleCitationCount":43,"googleAuthor":"R Coleman"},{"title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","googleId":"Saws194IJzUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349944","googleCitationCount":49,"googleAuthor":"M Lambertini"},{"title":"Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials","googleId":"YxGnAiwPREoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311317","googleCitationCount":34,"googleAuthor":"E Fontana"},{"title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","googleId":"2o93TR0d-F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345405","googleCitationCount":45,"googleAuthor":"IR White"},{"title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","googleId":"zpHVKPgqZhEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350070","googleCitationCount":48,"googleAuthor":"E Ghorani"},{"title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions","googleId":"GJWU25bDTYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345582","googleCitationCount":41,"googleAuthor":"EEW Cohen"},{"title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","googleId":"w99YVEXzsH0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341420","googleCitationCount":38,"googleAuthor":"F Scotté"},{"title":"CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer","googleId":"BRzdf1031OUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345491","googleCitationCount":41,"googleAuthor":""},{"title":"How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer","googleId":"5-2L4DxJ1PAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312037","googleCitationCount":32,"googleAuthor":"S Peters"},{"title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","googleId":"iRLLQHPhEfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312049","googleCitationCount":31,"googleAuthor":"C Ay"},{"title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","googleId":"_nzkQ6SAG-0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454781","googleCitationCount":43,"googleAuthor":"E Pectasides"},{"title":"Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","googleId":"iUFI1cMahvEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/abstract","googleCitationCount":35,"googleAuthor":"E Kastritis"},{"title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","googleId":"_TamHOAeuMwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345302","googleCitationCount":43,"googleAuthor":"W Jurczak"},{"title":"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE …","googleId":"Rfgoqy9ugfkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349002","googleCitationCount":42,"googleAuthor":"HG Wirsching"},{"title":"Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors","googleId":"OcT33W3-ynMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350525","googleCitationCount":47,"googleAuthor":"C Albany"},{"title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","googleId":"0m4C53yZBWQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342371","googleCitationCount":35,"googleAuthor":"MC Vegliante"},{"title":"Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) …","googleId":"exQLpop4URMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49923-7/abstract","googleCitationCount":43,"googleAuthor":""},{"title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","googleId":"IKVOgxvMniQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459875","googleCitationCount":46,"googleAuthor":"S Heeke"},{"title":"A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","googleId":"ftZkpvQEy4gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604187","googleCitationCount":30,"googleAuthor":"W Brady"},{"title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase …","googleId":"ldY6Wor-mcsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325576","googleCitationCount":37,"googleAuthor":"J Mizusawa"},{"title":"Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours","googleId":"Tgqxylw0bP4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586689","googleCitationCount":33,"googleAuthor":"MG Fakih"},{"title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with …","googleId":"XTj-dKLPALQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603601","googleCitationCount":30,"googleAuthor":""},{"title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","googleId":"c5uc3zECzYoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312281","googleCitationCount":35,"googleAuthor":"MD Hellmann"},{"title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish …","googleId":"7v36ISbrmggJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311081","googleCitationCount":30,"googleAuthor":"R Garcia-Sanz"},{"title":"Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II …","googleId":"Xi6pgvJcNVAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609816","googleCitationCount":24,"googleAuthor":""},{"title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)","googleId":"2YoX13n8AQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49078-9/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","googleId":"G2AOastoQf8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621721","googleCitationCount":33,"googleAuthor":""},{"title":"OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant …","googleId":"0tsNO6QGSpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350641","googleCitationCount":43,"googleAuthor":"DM Provencher"},{"title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the …","googleId":"wu2l1553meYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31045-2/abstract","googleCitationCount":39,"googleAuthor":"S Peters"},{"title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","googleId":"RVX2Q5TKAzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931155X","googleCitationCount":28,"googleAuthor":"S Sandhu"},{"title":"A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267","googleId":"lgJq764m2EkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355012","googleCitationCount":42,"googleAuthor":"J Gong"},{"title":"BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with …","googleId":"bF6-xN0csoQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311718","googleCitationCount":27,"googleAuthor":""},{"title":"IMpower132: efficacy of atezolizumab (atezo)+ carboplatin (carbo)/cisplatin (cis)+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous …","googleId":"sXw_bfOpDGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50457-4/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+ cobimetinib and atezolizumab monotherapy vs regorafenib in …","googleId":"g6KV-0HjOu8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34066-9/abstract","googleCitationCount":44,"googleAuthor":"F Ciardiello"},{"title":"Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and …","googleId":"QaKgNGYqg6AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604035","googleCitationCount":30,"googleAuthor":"MR Smith"},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","googleId":"EM4ODdMcr88J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43453-4/abstract","googleCitationCount":34,"googleAuthor":""},{"title":"Biological background of the genomic variations of cf-DNA in healthy individuals","googleId":"Vl0F2c7sxd4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310737","googleCitationCount":30,"googleAuthor":""},{"title":"Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in …","googleId":"Y27Ab4e_nEEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960983X","googleCitationCount":22,"googleAuthor":"G Villacampa"},{"title":"Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms","googleId":"thQg4b1NgbUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350756","googleCitationCount":39,"googleAuthor":"F Blackhall"},{"title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast …","googleId":"qxb0mfJK-zsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311615","googleCitationCount":33,"googleAuthor":""},{"title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","googleId":"8-5nGcFfh-IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931244X","googleCitationCount":32,"googleAuthor":"B Surmann"},{"title":"RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI …","googleId":"hg-h3xCw_0EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349762","googleCitationCount":48,"googleAuthor":"N Normanno"},{"title":"Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial","googleId":"vuVmkjkJ76AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587488","googleCitationCount":28,"googleAuthor":"A Cercek"},{"title":"Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and …","googleId":"nGtxw5h62GgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350549","googleCitationCount":39,"googleAuthor":"AM Udager"},{"title":"Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial","googleId":"WNw8KdGG1d8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311950","googleCitationCount":26,"googleAuthor":"I Garcia-Murillas"},{"title":"Registrational results of LOXO-292 in patients with RET-altered thyroid cancers","googleId":"0-t99iZiuDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604539","googleCitationCount":26,"googleAuthor":"A Drilon"},{"title":"Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC …","googleId":"JlSB7lImorUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321106","googleCitationCount":35,"googleAuthor":"J Mateo"},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were …","googleId":"7VJCiuB1Y_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33687-7/abstract","googleCitationCount":37,"googleAuthor":"F Meric-Bernstam"},{"title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"u-98sAqANuAJ","googleLink":"https://www.researchgate.net/profile/Fabio_Trippa/publication/325949870_Diarrhoea_in_adult_cancer_patients_ESMO_Clinical_Practice_Guidelines/links/5c9a73c545851506d72d9cff/Diarrhoea-in-adult-cancer-patients-ESMO-Clinical-Practice-Guidelines.pdf","googleCitationCount":37,"googleAuthor":"NI Cherny"},{"title":"Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment …","googleId":"O-BA9Uz0KpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603790","googleCitationCount":30,"googleAuthor":"J Taieb"},{"title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","googleId":"d9nlJM-GtpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348902","googleCitationCount":40,"googleAuthor":"F Pietrantonio"},{"title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","googleId":"nO4muLjCS34J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454884","googleCitationCount":33,"googleAuthor":"S Aspeslagh"},{"title":"Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer","googleId":"3EZHtU2FiRAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310233","googleCitationCount":30,"googleAuthor":""},{"title":"Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors","googleId":"stJ-r3IG89wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032562X","googleCitationCount":33,"googleAuthor":"J Vardy"},{"title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant …","googleId":"H9PCtq6DUYgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350446","googleCitationCount":44,"googleAuthor":""},{"title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","googleId":"ShcmN2lrzUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312700","googleCitationCount":31,"googleAuthor":"M Donoghue"},{"title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with …","googleId":"NcEKQkK9BeMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354821","googleCitationCount":39,"googleAuthor":"M Hutchings"},{"title":"Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast …","googleId":"aPOX45bC4y0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310877","googleCitationCount":29,"googleAuthor":"AA Brandes"},{"title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized …","googleId":"js2-M_CPsvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311585","googleCitationCount":30,"googleAuthor":""},{"title":"Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+ trastuzumab emtansine (T-DM1) vs …","googleId":"Mg52z8zrtAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585271","googleCitationCount":29,"googleAuthor":"LA Emens"},{"title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a …","googleId":"g2A1yxVoo3MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341298","googleCitationCount":33,"googleAuthor":"M Ignatiadis"},{"title":"Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?","googleId":"sSPFbNDwv74J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350689","googleCitationCount":38,"googleAuthor":"PC Chou"},{"title":"A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable …","googleId":"83ZYG67gc8oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50420-3/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Are liquid biopsies a surrogate for tissue EGFR testing?","googleId":"dZ0zv7H09PoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316722","googleCitationCount":35,"googleAuthor":"J Remon"},{"title":"Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification","googleId":"rF_cAGb2yhYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348999","googleCitationCount":36,"googleAuthor":""},{"title":"Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K …","googleId":"3xJWImk5ue0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343726","googleCitationCount":25,"googleAuthor":"D Eiger"},{"title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized …","googleId":"h-KmQLwSnKUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348951","googleCitationCount":37,"googleAuthor":"S Hayoz"},{"title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","googleId":"IhQez76oQiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312918","googleCitationCount":25,"googleAuthor":"P Nuciforo"},{"title":"Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite …","googleId":"x98I5RIl2xEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603959","googleCitationCount":27,"googleAuthor":"K Shitara"},{"title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"ZWpnw0ZzBBQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310920","googleCitationCount":33,"googleAuthor":""},{"title":"Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses","googleId":"EO2boc02XogJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454938","googleCitationCount":32,"googleAuthor":"PR Carr"},{"title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy …","googleId":"mkEum991BwIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931230X","googleCitationCount":23,"googleAuthor":""},{"title":"Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and …","googleId":"Aze7hvTc_BQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32760-7/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from …","googleId":"b3kGa1DtEb8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604497","googleCitationCount":22,"googleAuthor":"MC Garassino"},{"title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","googleId":"zgADMXTMMgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355085","googleCitationCount":38,"googleAuthor":""},{"title":"Gender medicine and oncology: report and consensus of an ESMO workshop","googleId":"NxybZTWA4R0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325643","googleCitationCount":25,"googleAuthor":"S Oertelt-Prigione"},{"title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","googleId":"6tfIGvxzDlcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311640","googleCitationCount":28,"googleAuthor":"JH Lee"},{"title":"Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO","googleId":"Y28UjvI_tF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454574","googleCitationCount":39,"googleAuthor":"C Cremolini"},{"title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","googleId":"oX-EbV8o7XwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350495","googleCitationCount":37,"googleAuthor":""},{"title":"Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study","googleId":"4-jXpDH9DOEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350586","googleCitationCount":38,"googleAuthor":""},{"title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 …","googleId":"eLDZdL4LwFsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934236X","googleCitationCount":29,"googleAuthor":"L Marandino"},{"title":"InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly …","googleId":"22-PQuHEO-8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50413-6/abstract","googleCitationCount":30,"googleAuthor":"S Rao"},{"title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the …","googleId":"eZA3ClSM_PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341997","googleCitationCount":28,"googleAuthor":""},{"title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","googleId":"MwOJQ9vxOyEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325941","googleCitationCount":27,"googleAuthor":"AR Ferreira"},{"title":"Phase II study of olaparib (O) and durvalumab (D)(MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast …","googleId":"TydcdbeVsAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594030","googleCitationCount":23,"googleAuthor":"S Postel-Vinay"},{"title":"Overview of the relevance of PI3K pathway in HR-positive breast cancer","googleId":"r3cKMq3JT7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343738","googleCitationCount":24,"googleAuthor":"N Vasan"},{"title":"Recent advances in circulating nucleic acids in oncology","googleId":"llW4tJsV08sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310919","googleCitationCount":27,"googleAuthor":""},{"title":"Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study","googleId":"Sl_YwOfw4wsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934548X","googleCitationCount":34,"googleAuthor":"CKY Ng"},{"title":"MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy …","googleId":"KXK8bYznZqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603728","googleCitationCount":21,"googleAuthor":""},{"title":"Molecular pathology of tumors of the central nervous system","googleId":"-OSUrllH0x0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312839","googleCitationCount":28,"googleAuthor":""},{"title":"Insulin resistance and body composition in cancer patients","googleId":"NSShSoL3hKMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316801","googleCitationCount":35,"googleAuthor":""},{"title":"Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform …","googleId":"f-zpVhV9gsoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35514-0/abstract","googleCitationCount":32,"googleAuthor":"R Herold"},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative …","googleId":"tFwE2CDFyu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310002","googleCitationCount":23,"googleAuthor":"F Lordick"},{"title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","googleId":"-q2ZBmdIUsQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348963","googleCitationCount":33,"googleAuthor":""},{"title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of …","googleId":"nKloUUhDlH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348975","googleCitationCount":28,"googleAuthor":""},{"title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","googleId":"8P5jNf2i44cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318897","googleCitationCount":34,"googleAuthor":"AD Colevas"},{"title":"Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer","googleId":"oT5RrFs8UbYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349786","googleCitationCount":37,"googleAuthor":"S Siena"},{"title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer","googleId":"Au9RDXHm_cMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341729","googleCitationCount":32,"googleAuthor":""},{"title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","googleId":"sWJkGW2cAN0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459942","googleCitationCount":28,"googleAuthor":"J Zhang"},{"title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","googleId":"vxP9MCH8BvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316709","googleCitationCount":37,"googleAuthor":"J Remon"},{"title":"Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications","googleId":"8Lhub5gERssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459814","googleCitationCount":20,"googleAuthor":"R Nicolle"},{"title":"Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)","googleId":"2loUKQP38moJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50466-5/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial","googleId":"RtZCCORwjCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49797-4/abstract","googleCitationCount":30,"googleAuthor":"K Brock"},{"title":"Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer","googleId":"9FTG-ZVFNYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342450","googleCitationCount":23,"googleAuthor":"Y Wan"},{"title":"Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of …","googleId":"TfuAuQSE-FUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354961","googleCitationCount":35,"googleAuthor":""},{"title":"BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab …","googleId":"_pbYZDbSygEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30959-7/abstract","googleCitationCount":25,"googleAuthor":"S Kopetz"},{"title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and …","googleId":"c1H9oTITIU8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355127","googleCitationCount":32,"googleAuthor":"AK Godwin"},{"title":"Evolutionary dynamics of residual disease in human glioblastoma","googleId":"2tBZ5ry8hPEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310725","googleCitationCount":23,"googleAuthor":"G Caravagna"},{"title":"Phase II study of olaparib+ durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","googleId":"FfyCXormmyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594029","googleCitationCount":21,"googleAuthor":""},{"title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","googleId":"3JFW5E76ihgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454823","googleCitationCount":29,"googleAuthor":"A Quintela"},{"title":"Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach","googleId":"Gxcr7M-j_jsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342395","googleCitationCount":26,"googleAuthor":"J Guigay"},{"title":"REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer …","googleId":"0IyMIZT1uYUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310336","googleCitationCount":25,"googleAuthor":"K Shitara"},{"title":"Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC","googleId":"jQjwSZkTEPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603984","googleCitationCount":25,"googleAuthor":"DG Duda"},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized …","googleId":"59XRyXBbRwcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341249","googleCitationCount":28,"googleAuthor":"MJ Maurer"},{"title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with …","googleId":"U-CCvi3pCCsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350380","googleCitationCount":34,"googleAuthor":"L Wang"},{"title":"Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 …","googleId":"xnKXuBOa33kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603844","googleCitationCount":20,"googleAuthor":"A Sartore-Bianchi"},{"title":"Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer","googleId":"YFb0XUsUREUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580139","googleCitationCount":17,"googleAuthor":"D Hyman"},{"title":"From hepatitis C virus infection to B-cell lymphoma","googleId":"Rlx4XBGYNr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349907","googleCitationCount":32,"googleAuthor":"E Bachy"},{"title":"Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma","googleId":"S2k0Z1pUAEAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320976","googleCitationCount":28,"googleAuthor":"J Lewin"},{"title":"Efficacy and safety of nivolumab (Nivo)+ ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358","googleId":"zMFU0IFcgp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604199","googleCitationCount":21,"googleAuthor":"RW Naumann"},{"title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","googleId":"bZoPXsZwPtMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349026","googleCitationCount":26,"googleAuthor":"FM Mancuso"},{"title":"An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies","googleId":"nnpcydVVlxkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591189","googleCitationCount":19,"googleAuthor":"R Jones"},{"title":"Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer","googleId":"nHN3cfhjJGYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50424-0/abstract","googleCitationCount":28,"googleAuthor":"ND James"},{"title":"Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach","googleId":"x1D2NaIvnm0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325862","googleCitationCount":14,"googleAuthor":"A Anazodo"},{"title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","googleId":"B_BuGIWqMwkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34190-0/abstract","googleCitationCount":27,"googleAuthor":"EP Scully"},{"title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor …","googleId":"G97EY5ClyK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345508","googleCitationCount":32,"googleAuthor":"F Lunardi"},{"title":"Bevacizumab+ chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial …","googleId":"r8X0HbEgJzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419351312","googleCitationCount":31,"googleAuthor":"J Taieb"},{"title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial","googleId":"cJUUvTTpos0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341432","googleCitationCount":26,"googleAuthor":""},{"title":"Progestin-associated shift of meningioma mutational landscape","googleId":"V90YADzxXlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354882","googleCitationCount":30,"googleAuthor":""},{"title":"Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for …","googleId":"smZ_tgrg7msJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310257","googleCitationCount":21,"googleAuthor":""},{"title":"Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)","googleId":"7e4fZViTeOkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591207","googleCitationCount":17,"googleAuthor":""},{"title":"Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?","googleId":"e8u8DQgTCh0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34114-6/abstract","googleCitationCount":29,"googleAuthor":"VJ Mar"},{"title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","googleId":"UlTYYiNbI9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312384","googleCitationCount":24,"googleAuthor":"K Nones"},{"title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung …","googleId":"8z2OHoHDekkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311603","googleCitationCount":22,"googleAuthor":""},{"title":"The Macrophage 'Do not eat me'signal, CD47, is a clinically validated cancer immunotherapy target","googleId":"ld6xbcHXvWcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31086-5/abstract","googleCitationCount":22,"googleAuthor":""},{"title":"Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the …","googleId":"rDvJA9goAgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350513","googleCitationCount":30,"googleAuthor":"MGE Verdam"},{"title":"IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab+ carboplatin+ paclitaxel or nab …","googleId":"qtda6Fnh9u8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50468-9/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials","googleId":"IOb38PUvRtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34240-1/abstract","googleCitationCount":25,"googleAuthor":"K Hess"},{"title":"Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens","googleId":"grujUqpfw64J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311974","googleCitationCount":19,"googleAuthor":"W Ye"},{"title":"Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium","googleId":"MWkCKOn1BfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341547","googleCitationCount":27,"googleAuthor":""},{"title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","googleId":"lNFfQDkVvhIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551171","googleCitationCount":21,"googleAuthor":"A Amatu"},{"title":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","googleId":"6Z2UXopOlXYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349981","googleCitationCount":31,"googleAuthor":"M Riester"},{"title":"Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden","googleId":"dqOK4yydhNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311706","googleCitationCount":22,"googleAuthor":""},{"title":"IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC)","googleId":"xdN7rYsjtF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598702","googleCitationCount":30,"googleAuthor":"AS Mansfield"},{"title":"De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","googleId":"ZhfooX04w4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311937","googleCitationCount":26,"googleAuthor":""},{"title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant …","googleId":"3r3mww53iX8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454690","googleCitationCount":26,"googleAuthor":"MJ Birrer"},{"title":"Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity","googleId":"CGr03QMpcLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316783","googleCitationCount":27,"googleAuthor":""},{"title":"Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)","googleId":"a2ySe8Qr7Z8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604114","googleCitationCount":25,"googleAuthor":"MO Grimm"},{"title":"Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma","googleId":"ueg1xNLivs4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311093","googleCitationCount":17,"googleAuthor":"JH Rasmussen"},{"title":"INVICTUS: a Phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as≥ 4th-line therapy in patients with …","googleId":"DYN4OGko_wYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604473","googleCitationCount":19,"googleAuthor":"H Gelderblom"},{"title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy","googleId":"jRlAdvzt20cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604205","googleCitationCount":17,"googleAuthor":""},{"title":"Advances in targeted alpha therapy for prostate cancer","googleId":"qeZvW6dmJH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325850","googleCitationCount":14,"googleAuthor":"G De Vincentis"},{"title":"Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial","googleId":"pvXM_NAmOz8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321040","googleCitationCount":28,"googleAuthor":"E Fokas"},{"title":"Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC …","googleId":"E4XkErDxfX8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49289-2/abstract","googleCitationCount":24,"googleAuthor":""},{"title":"The use of antidepressants in oncology: a review and practical tips for oncologists","googleId":"qU1Vmn_j-c4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349804","googleCitationCount":29,"googleAuthor":"L Grassi"},{"title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types","googleId":"crLgaWCIdLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342085","googleCitationCount":23,"googleAuthor":"T Pascual"},{"title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of …","googleId":"MSh6nWxhVTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311159","googleCitationCount":20,"googleAuthor":"L Danilova"},{"title":"Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"Ly-xjGYuG7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604412","googleCitationCount":16,"googleAuthor":"V Velcheti"},{"title":"Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer","googleId":"_VYZDZroF5kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354973","googleCitationCount":29,"googleAuthor":"BS Sørensen"},{"title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with …","googleId":"eXb0Pb9DxDEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350008","googleCitationCount":33,"googleAuthor":"P Nuciforo"},{"title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small …","googleId":"52y4nZCSp3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581212","googleCitationCount":17,"googleAuthor":""},{"title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","googleId":"JoRsCB8XTA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932109X","googleCitationCount":25,"googleAuthor":""},{"title":"Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies","googleId":"fJG7prhy-BoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355103","googleCitationCount":29,"googleAuthor":"EK Choi"},{"title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","googleId":"lS8eu5BjU1IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309998","googleCitationCount":21,"googleAuthor":"YX Feng"},{"title":"Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China","googleId":"o7MGi_c7O-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609750","googleCitationCount":14,"googleAuthor":""},{"title":"Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non …","googleId":"doO7r7oysoQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50481-1/abstract","googleCitationCount":23,"googleAuthor":"N Reguart"},{"title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","googleId":"9rmS9po1tKgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325989","googleCitationCount":24,"googleAuthor":""},{"title":"Triumph: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (PTS) with metastatic colorectal cancer (mCRC) with HER2 …","googleId":"n9BfcJJvHrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587476","googleCitationCount":20,"googleAuthor":"Y Nakamura"},{"title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","googleId":"TxgNThEKQucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934181X","googleCitationCount":24,"googleAuthor":"GH Lyman"},{"title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","googleId":"4NQc1m_sS90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354894","googleCitationCount":26,"googleAuthor":"TE Witzig"},{"title":"The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer","googleId":"42c2AQFuvg0J","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/334295334_O-013Impact_of_age_and_gender_on_safety_and_efficacy_of_first-line_FOLFOXIRIbevacizumab_in_mCRC_a_pooled_analysis_of_TRIBE_and_TRIBE2_studies/links/5dd2cbc3299bf1b74b4e18ec/O-013Impact-of-age-and-gender-on-safety-and-efficacy-of-first-line-FOLFOXIRI-bevacizumab-in-mCRC-a-pooled-analysis-of-TRIBE-and-TRIBE2-studies.pdf","googleCitationCount":19,"googleAuthor":"M Shah"},{"title":"Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma","googleId":"rbSkmHINoksJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350045","googleCitationCount":31,"googleAuthor":"SJ Kim"},{"title":"Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A …","googleId":"G_kf_BTjScMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49394-0/abstract","googleCitationCount":26,"googleAuthor":""},{"title":"MONARCH 2: overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer","googleId":"PVTN2slrZ5QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603662","googleCitationCount":18,"googleAuthor":"J Sohn"},{"title":"Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the …","googleId":"TuSfcSrt8BYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591268","googleCitationCount":17,"googleAuthor":"TK Choueiri"},{"title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma …","googleId":"-gH0bvWgbwEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50421-5/abstract","googleCitationCount":23,"googleAuthor":"S Roychowdhury"},{"title":"T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression","googleId":"Sep5QdX7cBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321003","googleCitationCount":27,"googleAuthor":"A Draghi"},{"title":"Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically …","googleId":"B4fBIsU9Q1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49217-X/abstract","googleCitationCount":22,"googleAuthor":"A Hollebecque"},{"title":"Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma","googleId":"6b-CHagAf4oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311986","googleCitationCount":17,"googleAuthor":"J Yu"},{"title":"A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma","googleId":"pTJeizM-EmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454616","googleCitationCount":24,"googleAuthor":"MY Wang"},{"title":"A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)","googleId":"Sg0McIKl18MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49397-6/abstract","googleCitationCount":24,"googleAuthor":"CM Annunziata"},{"title":"Current status of immune checkpoint inhibition in early-stage NSCLC","googleId":"F5k74PO6DsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931289X","googleCitationCount":20,"googleAuthor":""},{"title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","googleId":"jQUHhjHLuOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45455-0/abstract","googleCitationCount":27,"googleAuthor":"O Lambotte"},{"title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer …","googleId":"t7rM46hJoHcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355097","googleCitationCount":28,"googleAuthor":""},{"title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only …","googleId":"PSMJHz_g9HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934205X","googleCitationCount":26,"googleAuthor":""},{"title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","googleId":"gyxyVqAau4YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342097","googleCitationCount":24,"googleAuthor":"DB Costa"},{"title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)","googleId":"6Zw2I3UKrooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309810","googleCitationCount":21,"googleAuthor":""},{"title":"Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric …","googleId":"1A8_QawQBrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603947","googleCitationCount":19,"googleAuthor":"YK Kang"},{"title":"Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic …","googleId":"7hFAPDMoQdsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309792","googleCitationCount":20,"googleAuthor":"G Bodoky"},{"title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International …","googleId":"xQbj7CEj29kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350392","googleCitationCount":26,"googleAuthor":"A Bamias"},{"title":"Nivolumab (NIVO)+ low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung …","googleId":"M1pTCaU6dAYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604357","googleCitationCount":15,"googleAuthor":"S Peters"},{"title":"Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial","googleId":"XkJC-HzspRsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342024","googleCitationCount":21,"googleAuthor":""},{"title":"Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer","googleId":"58qX7XXIVQgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931021X","googleCitationCount":17,"googleAuthor":"RD Nipp"},{"title":"A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer","googleId":"xFuVGlEqvyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350100","googleCitationCount":27,"googleAuthor":""},{"title":"FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus …","googleId":"yvVADTcEIYAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592055","googleCitationCount":15,"googleAuthor":"N Colombo"},{"title":"Advances in the systemic treatment of melanoma brain metastases","googleId":"8Eis8SZnbawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321143","googleCitationCount":20,"googleAuthor":""},{"title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal …","googleId":"rrb4MMBTzvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311160","googleCitationCount":18,"googleAuthor":""},{"title":"Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy","googleId":"X3FpqKpxPOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312438","googleCitationCount":22,"googleAuthor":""},{"title":"HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?","googleId":"AYg7pe0SmcUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34119-5/abstract","googleCitationCount":26,"googleAuthor":"S Mahner"},{"title":"Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the …","googleId":"hohreMbynu8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350665","googleCitationCount":26,"googleAuthor":"JM Ordóñez-Mena"},{"title":"Meeting report from the joint IARC–NCI International cancer seminar series: a focus on colorectal cancer","googleId":"DsrZK-Rp-gUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311251","googleCitationCount":17,"googleAuthor":"MJ Gunter"},{"title":"Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies","googleId":"swBGN60j_j8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593863","googleCitationCount":15,"googleAuthor":"D Le"},{"title":"Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of …","googleId":"iIQVL6SPcWkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604096","googleCitationCount":15,"googleAuthor":"N Agarwal"},{"title":"Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in …","googleId":"Nyb_mj5OEWoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603935","googleCitationCount":20,"googleAuthor":""},{"title":"A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","googleId":"7opP6sVHBi8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50430-6/abstract","googleCitationCount":22,"googleAuthor":"C Albany"},{"title":"Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib","googleId":"M-zIDvNotN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032559X","googleCitationCount":12,"googleAuthor":"P Hammel"},{"title":"Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer …","googleId":"I0p5ITwTiz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310373","googleCitationCount":17,"googleAuthor":"PM Webb"},{"title":"Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer","googleId":"BbjhiPIAHV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931885X","googleCitationCount":22,"googleAuthor":"AJ Armstrong"},{"title":"Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis","googleId":"jIjfB10CDSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345429","googleCitationCount":20,"googleAuthor":""},{"title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","googleId":"reD3H_rI-_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45459-8/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","googleId":"SIU1amTP2bwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551195","googleCitationCount":21,"googleAuthor":"EM O'reilly"},{"title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","googleId":"2-7H6KWmKREJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345442","googleCitationCount":20,"googleAuthor":""},{"title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for …","googleId":"UIRHWToeoOoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345506","googleCitationCount":13,"googleAuthor":""},{"title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+ IPI) combination therapy in advanced melanoma","googleId":"3GXbb48SKIEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604254","googleCitationCount":11,"googleAuthor":"JMG Larkin"},{"title":"Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …","googleId":"uKQP4Wz61dgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325540","googleCitationCount":16,"googleAuthor":""},{"title":"Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An …","googleId":"cZ5XBovNdmwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604102","googleCitationCount":14,"googleAuthor":"RS Kaplan"},{"title":"Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium","googleId":"8FMktI4iiF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312712","googleCitationCount":17,"googleAuthor":""},{"title":"Stevens–Johnson syndrome during nivolumab treatment of NSCLC","googleId":"uAc3wAiT0LgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34995-6/abstract","googleCitationCount":26,"googleAuthor":"F Bertolini"},{"title":"Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations","googleId":"vlUUT8WS6uYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49503-3/abstract","googleCitationCount":22,"googleAuthor":"AL Ho"},{"title":"Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)","googleId":"BzXj6JTEc9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604345","googleCitationCount":14,"googleAuthor":"GR Oxnard"},{"title":"Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line …","googleId":"ez8qmwSqUAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341286","googleCitationCount":20,"googleAuthor":""},{"title":"A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","googleId":"oKawZ9q_OwUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32642-0/abstract","googleCitationCount":25,"googleAuthor":"J Abramson"},{"title":"EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort …","googleId":"DKytDmeaZZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325928","googleCitationCount":21,"googleAuthor":"J Bellmunt"},{"title":"Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial","googleId":"3LMeyIHHBPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582254","googleCitationCount":14,"googleAuthor":"HR Kim"},{"title":"Cancer mortality in Europe in 2015 and an overview of trends since 1990","googleId":"DmXfIFSav7MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312931","googleCitationCount":12,"googleAuthor":"P Bertuccio"},{"title":"Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer","googleId":"Ss2zX1CeqbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310749","googleCitationCount":18,"googleAuthor":"AM Ben-David"},{"title":"Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial","googleId":"7VrYy7MOOYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49253-3/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors","googleId":"-U42AytoZk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590615","googleCitationCount":14,"googleAuthor":"ES Antonarakis"},{"title":"A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer","googleId":"YjsZe06k-poJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49398-8/abstract","googleCitationCount":21,"googleAuthor":""},{"title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK …","googleId":"XQR-ImLJkfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325953","googleCitationCount":29,"googleAuthor":"HJ Lenz"},{"title":"Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer","googleId":"WI68VFTWPK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310798","googleCitationCount":18,"googleAuthor":"R Sundar"},{"title":"Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled …","googleId":"5MK2c0hYhzkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341626","googleCitationCount":19,"googleAuthor":"HJ Lenz"},{"title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study","googleId":"6-m33z3H0nkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50050-3/abstract","googleCitationCount":18,"googleAuthor":"I Bondarenko"},{"title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final …","googleId":"3pBPcxo6FFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350094","googleCitationCount":25,"googleAuthor":"A du Bois"},{"title":"3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo) adjuvant ipilimumab (IPI)+ nivolumab (NIVO) in macroscopic stage III …","googleId":"EIlLpk01leoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595242","googleCitationCount":13,"googleAuthor":"CU Blank"},{"title":"LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non …","googleId":"E7cPqiQtX3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034549X","googleCitationCount":12,"googleAuthor":"RS Herbst"},{"title":"Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort","googleId":"QDf00-oG_A0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604394","googleCitationCount":17,"googleAuthor":"S Peters"},{"title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","googleId":"RusJqw5o9F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348987","googleCitationCount":19,"googleAuthor":"T Murata"},{"title":"A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the …","googleId":"nI_nTyI351kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342309","googleCitationCount":17,"googleAuthor":"EC Smyth"},{"title":"Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel (D), oxaliplatin (O) and S-1 (S)(DOS) followed by surgery and adjuvant S-1, vs …","googleId":"Td3McEwog0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603923","googleCitationCount":16,"googleAuthor":"YK Kang"},{"title":"Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their …","googleId":"6EwgpzkqDNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341559","googleCitationCount":23,"googleAuthor":"Z Sztupinszki"},{"title":"Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial","googleId":"R7Zbo3ROuJwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341237","googleCitationCount":20,"googleAuthor":"V Scott"},{"title":"Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant …","googleId":"MZkk_g1ZvK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604230","googleCitationCount":12,"googleAuthor":"DE Gyorki"},{"title":"TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers","googleId":"XRSQh-bBR4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587282","googleCitationCount":13,"googleAuthor":"A Drilon"},{"title":"Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers","googleId":"3CGS3IsilM4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318836","googleCitationCount":17,"googleAuthor":"D Głodzik"},{"title":"A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ …","googleId":"fRhXJknAZ0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311949","googleCitationCount":18,"googleAuthor":"J Veeraraghavan"},{"title":"Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma","googleId":"R2Qwv5iK2DUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312001","googleCitationCount":14,"googleAuthor":"AD King"},{"title":"Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC","googleId":"dnFv8ZEF0TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32757-7/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Development of adaptive immune effector therapies in solid tumors","googleId":"pn7jB1r8bZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325874","googleCitationCount":10,"googleAuthor":"F Lanza"},{"title":"ARCTIC: Durvalumab+ tremelimumab and durvalumab monotherapy vs SoC in≥ 3L advanced NSCLC treatment","googleId":"kdfctA5xk9MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49791-3/abstract","googleCitationCount":18,"googleAuthor":"SV Orlov"},{"title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","googleId":"k7UyrTgk3mUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341183","googleCitationCount":18,"googleAuthor":""},{"title":"Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer","googleId":"QRoFFWkU-ZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932112X","googleCitationCount":17,"googleAuthor":"L Horn"},{"title":"The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?","googleId":"g8tUvyl-4UYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345375","googleCitationCount":22,"googleAuthor":"A Grothey"},{"title":"Neuronal autoantibodies associated with cognitive impairment in melanoma patients","googleId":"ZfHJQDb-fMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931169X","googleCitationCount":16,"googleAuthor":""},{"title":"Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the …","googleId":"lRNtKpufmv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349889","googleCitationCount":20,"googleAuthor":""},{"title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket'trial","googleId":"pi-01BkZC7QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30513-7/abstract","googleCitationCount":17,"googleAuthor":"J Harding"},{"title":"Pembrolizumab (pembro)+ chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in …","googleId":"L7XK79b7QqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604400","googleCitationCount":13,"googleAuthor":""},{"title":"BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) …","googleId":"u-bpLVJKA18J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587543","googleCitationCount":11,"googleAuthor":"TR Halfdanarson"},{"title":"Cancer mortality in the elderly in 11 countries worldwide, 1970–2015","googleId":"9nB-JV49mk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931292X","googleCitationCount":11,"googleAuthor":"M Malvezzi"},{"title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","googleId":"QrolSTmxn5IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309809","googleCitationCount":16,"googleAuthor":"IR Weir"},{"title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","googleId":"71ltQAxZVHgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935063X","googleCitationCount":20,"googleAuthor":""},{"title":"Translational insights into gastrointestinal stromal tumor and current clinical advances","googleId":"zuZ7BhGK_6oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341961","googleCitationCount":14,"googleAuthor":"MC Heinrich"},{"title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective …","googleId":"W4mtmUjUBisJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311263","googleCitationCount":15,"googleAuthor":"L Abar"},{"title":"Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence …","googleId":"rKo_d3VxsaYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604242","googleCitationCount":10,"googleAuthor":"D Schadendorf"},{"title":"EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","googleId":"LjYPNpazzngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591177","googleCitationCount":12,"googleAuthor":""},{"title":"LBA3 Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC …","googleId":"UB47kBIJdJ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034552X","googleCitationCount":10,"googleAuthor":""},{"title":"Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients","googleId":"2ZkMv8lgAx8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934164X","googleCitationCount":17,"googleAuthor":"J Fredsøe"},{"title":"Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath","googleId":"YhpGzTX_1DcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609828","googleCitationCount":17,"googleAuthor":"M Muller"},{"title":"Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) …","googleId":"wEhNMgAOtrQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30051-1/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and …","googleId":"0B_6P--tdXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341717","googleCitationCount":16,"googleAuthor":"CA Voltin"},{"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower …","googleId":"jvU9psOBTO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459905","googleCitationCount":19,"googleAuthor":"O Türeci"},{"title":"Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain …","googleId":"Ew02-3G-JAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350562","googleCitationCount":19,"googleAuthor":""},{"title":"Human endogenous retroviruses and their implication for immunotherapeutics of cancer","googleId":"ReeXC9-NowMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318915","googleCitationCount":21,"googleAuthor":"AM Bjerregaard"},{"title":"Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a …","googleId":"v-VNA55SDYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311226","googleCitationCount":18,"googleAuthor":"Y Bi"},{"title":"Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to …","googleId":"KOG_AcRQSzsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596867","googleCitationCount":11,"googleAuthor":""},{"title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","googleId":"vrXLOmpkcssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31280-3/abstract","googleCitationCount":14,"googleAuthor":"JY Blay"},{"title":"Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001 …","googleId":"Xn06f8Ktfq0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596909","googleCitationCount":11,"googleAuthor":"AS Mansfield"},{"title":"Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) …","googleId":"7OjVEeecLcYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604266","googleCitationCount":12,"googleAuthor":"H Gogas"},{"title":"Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas","googleId":"sPCILO20Tw8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341158","googleCitationCount":17,"googleAuthor":"T Lesluyes"},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407","googleId":"whQ4QbeLsfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596910","googleCitationCount":14,"googleAuthor":""},{"title":"Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or …","googleId":"6y7OCylAkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341742","googleCitationCount":16,"googleAuthor":"RL Jones"},{"title":"KEYNOTE-427 cohort A: pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","googleId":"6w9xRMIoNboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49260-0/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"On the need to adjust for multiplicity in confirmatory clinical trials with master protocols","googleId":"YN3bWWuIEqMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6503623/","googleCitationCount":13,"googleAuthor":""},{"title":"Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ …","googleId":"HHxIrzN0D90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609804","googleCitationCount":8,"googleAuthor":"RJ Young"},{"title":"Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?","googleId":"HSL2uEL21x4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350598","googleCitationCount":18,"googleAuthor":"GD Stewart"},{"title":"Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration …","googleId":"h-isco5sVRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590639","googleCitationCount":10,"googleAuthor":"JS de Bono"},{"title":"Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 …","googleId":"W42m9bsjJEkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50429-X/abstract","googleCitationCount":16,"googleAuthor":"P Sharma"},{"title":"Three-versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology …","googleId":"C5docYF6XnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312980","googleCitationCount":11,"googleAuthor":"J Souglakos"},{"title":"Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project","googleId":"5wKE82e5TP4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45492-6/abstract","googleCitationCount":21,"googleAuthor":"C Turnbull"},{"title":"Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) …","googleId":"Zoq1NlqiFYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48485-8/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative …","googleId":"SBxqqFC1CaQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50473-2/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"28wh4aQLRL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30062-6/abstract","googleCitationCount":13,"googleAuthor":"RC Doebele"},{"title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the …","googleId":"aYqOwqacxX4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318770","googleCitationCount":13,"googleAuthor":"E Calvo"},{"title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)","googleId":"T_ZkwSFNi9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50450-1/abstract","googleCitationCount":16,"googleAuthor":"T Cascone"},{"title":"Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164","googleId":"fum4WBDNkx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33707-X/abstract","googleCitationCount":16,"googleAuthor":"D Le"},{"title":"Phase II study evaluating trifluridine/tipiracil+ bevacizumab and capecitabine+ bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients …","googleId":"JV5gyM7CEboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33708-1/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Different menopausal hormone regimens and risk of breast cancer","googleId":"KoDhSU0EaOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341304","googleCitationCount":13,"googleAuthor":"N Brusselaers"},{"title":"Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial","googleId":"68rXpXmeGXsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30419-3/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","googleId":"ZF82SFTckCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349920","googleCitationCount":19,"googleAuthor":"S Jain"},{"title":"Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma …","googleId":"RNuAT5d9ahwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49086-8/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt","googleId":"J0z1b6T62TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33755-X/abstract","googleCitationCount":15,"googleAuthor":"H Elghazaly"},{"title":"Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy","googleId":"bYVAfJ7ElAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310853","googleCitationCount":12,"googleAuthor":"J Vidal"},{"title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","googleId":"PfzOf6mXy14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318903","googleCitationCount":19,"googleAuthor":""},{"title":"Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC","googleId":"-TYPnW4rfi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49776-7/abstract","googleCitationCount":14,"googleAuthor":"C Faivre-Finn"},{"title":"A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head …","googleId":"nKmlcJ_x_tUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49501-X/abstract","googleCitationCount":16,"googleAuthor":"EEW Cohen"},{"title":"Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-or FOLFIRINOX-based induction chemotherapy (NEOLAP) …","googleId":"ljWYHnSvVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588913","googleCitationCount":13,"googleAuthor":""},{"title":"Activity of larotrectinib in TRK fusion lung cancer","googleId":"XIBRQdmZkL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30060-2/abstract","googleCitationCount":12,"googleAuthor":"A Drilon"},{"title":"Initial results of Phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior …","googleId":"sSIojlFg_bQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50068-0/abstract","googleCitationCount":14,"googleAuthor":"M Heinrich"},{"title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a …","googleId":"d83tG3ZZQn4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32591-6/abstract","googleCitationCount":11,"googleAuthor":"J Remon"},{"title":"Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2","googleId":"URsX6_3tfgEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342103","googleCitationCount":12,"googleAuthor":"K Chang"},{"title":"Phase II study of tepotinib+ gefitinib (TEP+ GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)","googleId":"-IR_F2bHA5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49790-1/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Durvalumab activity in previously treated patients who stopped durvalumab without disease progression","googleId":"ZDJIpcmjKtsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593875","googleCitationCount":7,"googleAuthor":"JC Soria"},{"title":"A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors","googleId":"lwi5Pm4ueKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32724-3/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) …","googleId":"8pwtEE2GtV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595229","googleCitationCount":10,"googleAuthor":"GV Long"},{"title":"Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors","googleId":"hmakyT2ThpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309901","googleCitationCount":12,"googleAuthor":""},{"title":"Struggling with nutrition in patients with advanced cancer: Nutrition and nourishment—focusing on metabolism and supportive care","googleId":"4JlfDG4yCFcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316813","googleCitationCount":13,"googleAuthor":""},{"title":"Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ …","googleId":"_IUT7LbfCD8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596922","googleCitationCount":8,"googleAuthor":""},{"title":"NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis","googleId":"W6HxnPjeaW0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311998","googleCitationCount":8,"googleAuthor":""},{"title":"Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers","googleId":"DTxfE1-adboJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454872","googleCitationCount":15,"googleAuthor":"NJ Birkbak"},{"title":"Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune …","googleId":"N0YY9E9vWZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30016-X/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018","googleId":"rpvmicisVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342152","googleCitationCount":13,"googleAuthor":""},{"title":"Prognostic markers for colorectal cancer: estimating ploidy and stroma","googleId":"AEp90PAaGGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935505X","googleCitationCount":28,"googleAuthor":"HE Danielsen"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort","googleId":"hfyI4X625RsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49505-7/abstract","googleCitationCount":14,"googleAuthor":"A Ravaud"},{"title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)","googleId":"SUZ9CGVFySsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586665","googleCitationCount":8,"googleAuthor":"A Drilon"},{"title":"Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)","googleId":"R7Q2jxfXe6sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454902","googleCitationCount":13,"googleAuthor":""},{"title":"A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results …","googleId":"6i5UummQzPYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50049-7/abstract","googleCitationCount":15,"googleAuthor":"JL Pujol"},{"title":"Corrections to “Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"W2kW2oceqAcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31701-6/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding","googleId":"PMmSXqJi_LQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355061","googleCitationCount":16,"googleAuthor":"PF Thall"},{"title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic …","googleId":"KzjZjdRKzpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321088","googleCitationCount":15,"googleAuthor":"L Schwartzberg"},{"title":"Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","googleId":"Rw-_3Hq-l-UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341663","googleCitationCount":12,"googleAuthor":"B Basu"},{"title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","googleId":"Gs_18euEWSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355024","googleCitationCount":15,"googleAuthor":"AF Herrera"},{"title":"Avoiding over-and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","googleId":"tnCSfKiAFEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312347","googleCitationCount":12,"googleAuthor":"A Matikas"},{"title":"Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote …","googleId":"vTTAnrfAo-UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49733-0/abstract","googleCitationCount":15,"googleAuthor":"CU Blank"},{"title":"Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial","googleId":"rI-CjIc7UEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)59320-6/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 …","googleId":"oPZk42tSSQoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350653","googleCitationCount":15,"googleAuthor":"D Cella"},{"title":"18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) …","googleId":"PRMOPP4n9DYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604321","googleCitationCount":8,"googleAuthor":"AM Menzies"},{"title":"Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)","googleId":"IIGNdluRZEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598726","googleCitationCount":9,"googleAuthor":""},{"title":"Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)","googleId":"1o27HQJgVNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49268-5/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment","googleId":"6C2RUZpSm1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341614","googleCitationCount":11,"googleAuthor":""},{"title":"BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib+ MEK inhibitor binimetinib+ anti–epidermal growth factor receptor antibody …","googleId":"i78V2ZpoX7AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33713-5/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)","googleId":"wI2O4utGDfcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959528X","googleCitationCount":8,"googleAuthor":"D Rischin"},{"title":"Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)","googleId":"Jy3jJ8va4gMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592079","googleCitationCount":8,"googleAuthor":"V Makker"},{"title":"Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)","googleId":"2goHhcDf9kIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945463X","googleCitationCount":16,"googleAuthor":"JP Machiels"},{"title":"Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC","googleId":"uYSpjXssdI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50453-7/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous …","googleId":"QH2-VdfZMYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604175","googleCitationCount":7,"googleAuthor":"PA Konstantinopoulos"},{"title":"Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in …","googleId":"ZcMyUm9_bLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349932","googleCitationCount":17,"googleAuthor":""},{"title":"CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications","googleId":"EbEPj3dhQLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454835","googleCitationCount":16,"googleAuthor":""},{"title":"Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402 …","googleId":"fXs_21pmSw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49702-0/abstract","googleCitationCount":12,"googleAuthor":"JMP Rodriguez"},{"title":"Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess","googleId":"CxpwHk0n__EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32593-X/abstract","googleCitationCount":7,"googleAuthor":"J Ciccolini"},{"title":"Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer","googleId":"AyA8rab9h-YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310415","googleCitationCount":9,"googleAuthor":"T Huang"},{"title":"Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in checkmate 9KD","googleId":"6ZJbXrwKE1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604059","googleCitationCount":6,"googleAuthor":""},{"title":"Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice","googleId":"wYOPlx1Qcz0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349890","googleCitationCount":15,"googleAuthor":"D Cunningham"},{"title":"Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) in patients (pts) with BRAF-mutated metastatic …","googleId":"hKdrcqMzaLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595230","googleCitationCount":9,"googleAuthor":""},{"title":"Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: pooled analysis from KEYNOTE-010 …","googleId":"ZLNLGxi6yekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30052-3/abstract","googleCitationCount":12,"googleAuthor":"P Baas"},{"title":"Hyperprogression during immunotherapy: do we really want to know?","googleId":"ZmOi6P0b4ekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31252-9/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …","googleId":"6tYypZ2h6ZsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454847","googleCitationCount":18,"googleAuthor":""},{"title":"Atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study","googleId":"64oxgXJJl6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43117-7/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","googleId":"uNP2m2WV8e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592572","googleCitationCount":6,"googleAuthor":""},{"title":"Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)","googleId":"QcO9t0yY9KkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604126","googleCitationCount":8,"googleAuthor":"IB Vergote"},{"title":"Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib+ trametinib (D+ T) in patients (pts) with resected BRAF V600 …","googleId":"JsQPi7YFWAQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50444-6/abstract","googleCitationCount":13,"googleAuthor":"GV Long"},{"title":"Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated …","googleId":"axZKfNw5nEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604424","googleCitationCount":7,"googleAuthor":"S Azevedo"},{"title":"Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab","googleId":"cMlfn6VU-ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598751","googleCitationCount":6,"googleAuthor":"D Daniel"},{"title":"Benefit of prostate radiotherapy for patients with lymph node only or< 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site …","googleId":"SpuphOViGsoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590664","googleCitationCount":8,"googleAuthor":"ND James"},{"title":"Intratumoral (it) injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (IPI) triggers durable responses in PD-1 inhibitor refractory …","googleId":"cO0sU3L7qqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49700-7/abstract","googleCitationCount":11,"googleAuthor":"C Bernatchez"},{"title":"Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial","googleId":"Oy7HXk1zuqQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454768","googleCitationCount":14,"googleAuthor":"E Itti"},{"title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","googleId":"GH5N_3OE6AoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311767","googleCitationCount":10,"googleAuthor":"SN Westin"},{"title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase …","googleId":"2hoJ72fIdV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311123","googleCitationCount":10,"googleAuthor":"S Delaloge"},{"title":"Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer","googleId":"9NlQ6H8tKXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350604","googleCitationCount":15,"googleAuthor":"DD Yang"},{"title":"Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients …","googleId":"Mqc4-PyeEJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30534-4/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","googleId":"aYF3EntCHi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34107-9/abstract","googleCitationCount":15,"googleAuthor":"V Subbiah"},{"title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","googleId":"PjjArsRkw-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49609-9/abstract","googleCitationCount":10,"googleAuthor":"R Leidner"},{"title":"CCTG IND. 231: a phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","googleId":"4uKDHuV3B-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32636-5/abstract","googleCitationCount":15,"googleAuthor":"DW Cescon"},{"title":"Phase (Ph) II study of MBG453+ spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy","googleId":"1iXmwrgh7_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594145","googleCitationCount":7,"googleAuthor":"DW Kim"},{"title":"A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","googleId":"40Oc9WgQXiIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32634-1/abstract","googleCitationCount":15,"googleAuthor":"J Abramson"},{"title":"Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure …","googleId":"Hsrby8tNKUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345296","googleCitationCount":12,"googleAuthor":"YK Kang"},{"title":"Molecular screening to select therapy for advanced cancer?","googleId":"7DkpRHL1apYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31172-X/abstract","googleCitationCount":11,"googleAuthor":"IF Tannock"},{"title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","googleId":"u31LmrWx5v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312359","googleCitationCount":10,"googleAuthor":"RJ Kelly"},{"title":"Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","googleId":"Fh_YjwOALCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597368","googleCitationCount":7,"googleAuthor":"TM Kim"},{"title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","googleId":"OIehBdTihvwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345454","googleCitationCount":14,"googleAuthor":"JR Infante"},{"title":"Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced …","googleId":"WLbR1J3w_A0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49163-1/abstract","googleCitationCount":11,"googleAuthor":"T Meyer"},{"title":"Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration …","googleId":"x-7m5RVTDDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609762","googleCitationCount":6,"googleAuthor":"R Kurzrock"},{"title":"Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1 …","googleId":"QtTaE6_4btYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945480X","googleCitationCount":11,"googleAuthor":""},{"title":"Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated","googleId":"eJ5hosmQbnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344252","googleCitationCount":6,"googleAuthor":"A De Giglio"},{"title":"EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","googleId":"boqZl4EOZzoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454653","googleCitationCount":13,"googleAuthor":""},{"title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the …","googleId":"b6E2Ur4zWawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355073","googleCitationCount":14,"googleAuthor":"CK Lee"},{"title":"ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly …","googleId":"lbsUPJQO2zYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50426-4/abstract","googleCitationCount":12,"googleAuthor":"F Saad"},{"title":"Updated overall survival (OS) from extended follow up in ARCHER 1050: a randomized Phase III study comparing dacomitinib with gefitinib as first-line …","googleId":"YN1Kh9RfAu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582230","googleCitationCount":6,"googleAuthor":""},{"title":"Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?","googleId":"s8cL_m4puMIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35013-6/abstract","googleCitationCount":12,"googleAuthor":"M Fiorentino"},{"title":"Expression III: patients' expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO …","googleId":"KOASZnTMoL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454811","googleCitationCount":12,"googleAuthor":"S Alavi"},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously …","googleId":"MSJ5QK4RFF8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43122-0/abstract","googleCitationCount":10,"googleAuthor":"F Meric-Bernstam"},{"title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it","googleId":"YoEFZIdJIZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35074-4/abstract","googleCitationCount":14,"googleAuthor":"V Prasad"},{"title":"No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort …","googleId":"I3HqJpuqZmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934894X","googleCitationCount":12,"googleAuthor":"DC Muller"},{"title":"Validation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma","googleId":"lckIDNYs8wgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595357","googleCitationCount":7,"googleAuthor":"D Tempel"},{"title":"Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer","googleId":"rXGjs_y8pU4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32638-9/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study","googleId":"9Rbe3njT4QkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342449","googleCitationCount":8,"googleAuthor":"BP Hobbs"},{"title":"Nivolumab in non-small-cell lung cancer with EGFR mutation","googleId":"CgfPpTQire8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35486-9/abstract","googleCitationCount":13,"googleAuthor":"YH Kim"},{"title":"Management of toxicity to isoform α-specific PI3K inhibitors","googleId":"9TTVrHvfHxAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343763","googleCitationCount":12,"googleAuthor":""},{"title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers","googleId":"FQcv3-eYVm8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342115","googleCitationCount":10,"googleAuthor":""},{"title":"Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up","googleId":"5BzUywwZaEgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49321-6/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) …","googleId":"aPKEGScWGv4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589372","googleCitationCount":5,"googleAuthor":"A Hollebecque"},{"title":"Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma …","googleId":"l6JJo1kXZW4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588974","googleCitationCount":7,"googleAuthor":"T Meyer"},{"title":"FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the …","googleId":"k_cjYQxhFnYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587440","googleCitationCount":5,"googleAuthor":"D Morton"},{"title":"Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer","googleId":"7JP9nIFlCLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341171","googleCitationCount":9,"googleAuthor":"FR Hirsch"},{"title":"Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the …","googleId":"isw9la_ioCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590597","googleCitationCount":9,"googleAuthor":"MR Smith"},{"title":"Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or …","googleId":"xMKTts7-O1sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49123-0/abstract","googleCitationCount":11,"googleAuthor":"S Kondo"},{"title":"Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): the phase III ATTRACTION-3 study","googleId":"N0EdnZcrUSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603881","googleCitationCount":7,"googleAuthor":"M Takahashi"},{"title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and …","googleId":"gIQR-2j1Y6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325588","googleCitationCount":10,"googleAuthor":"S Lonardi"},{"title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) …","googleId":"l9k_1iz6fEoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591633","googleCitationCount":5,"googleAuthor":"TK Choueiri"},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"2yPh6yh2ulIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30053-5/abstract","googleCitationCount":11,"googleAuthor":"DWT Lim"},{"title":"Making immunotherapy 'cold'tumours 'hot'by chemotherapy-induced mutations—a misconception","googleId":"P2_ewO_wzVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31089-0/abstract","googleCitationCount":9,"googleAuthor":"T Helleday"},{"title":"Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer","googleId":"BJMq0Cpl0u0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341638","googleCitationCount":11,"googleAuthor":"JC Soria"},{"title":"Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or …","googleId":"The5kMy8YSkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585301","googleCitationCount":6,"googleAuthor":"MA Colleoni"},{"title":"INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II …","googleId":"VdNs2SrAoL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581819","googleCitationCount":7,"googleAuthor":"JCH Yang"},{"title":"A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials","googleId":"GWZ3oyaCQh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342346","googleCitationCount":8,"googleAuthor":"C Wayant"},{"title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","googleId":"W-YwwoO5kkoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341390","googleCitationCount":9,"googleAuthor":"M Oliva"},{"title":"A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC","googleId":"46Bv31sYuJEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959127X","googleCitationCount":5,"googleAuthor":"E Jonasch"},{"title":"Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a …","googleId":"mDKlvjyCsmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934565X","googleCitationCount":10,"googleAuthor":""},{"title":"Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized …","googleId":"yR1dG1NTmbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604333","googleCitationCount":7,"googleAuthor":""},{"title":"MONARCHplus: a phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast …","googleId":"lkSmc2IP4c8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603741","googleCitationCount":6,"googleAuthor":""},{"title":"JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results","googleId":"-Jcm_XzhbzsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49908-0/abstract","googleCitationCount":9,"googleAuthor":"JS Lee"},{"title":"LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood …","googleId":"rphT06jAE5oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345488","googleCitationCount":4,"googleAuthor":"RS Herbst"},{"title":"Keynote-407 China extension study: pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC","googleId":"Fe-OFza8cSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582242","googleCitationCount":6,"googleAuthor":""},{"title":"Phase III study of gefitinib (G) versus gefitinib+ carboplatin+ pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer …","googleId":"bU4S9l_diEsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49795-0/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer …","googleId":"6sYSgzh7bLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344264","googleCitationCount":7,"googleAuthor":"A Drakaki"},{"title":"OpACIN-neo: a multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)","googleId":"FbykJDO-4GwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50443-4/abstract","googleCitationCount":11,"googleAuthor":"CU Blank"},{"title":"The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma","googleId":"fOS_3nB9Y8sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350458","googleCitationCount":12,"googleAuthor":"F Bertucci"},{"title":"Nivolumab plus low-dose IPILIMUMAB as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817","googleId":"ICPr6eSAdRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344793","googleCitationCount":6,"googleAuthor":""},{"title":"Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) …","googleId":"YQKTst0WitMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50400-8/abstract","googleCitationCount":10,"googleAuthor":"M Cristofanilli"},{"title":"Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers","googleId":"uxWyi4nJSngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594224","googleCitationCount":5,"googleAuthor":""},{"title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","googleId":"12cCb0AAurYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350082","googleCitationCount":13,"googleAuthor":""},{"title":"Redefining the IGCCCG classification in advanced non-seminoma","googleId":"snClG7sVDIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591190","googleCitationCount":7,"googleAuthor":"G Daugaard"},{"title":"Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors","googleId":"EbBelKVZwlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312086","googleCitationCount":8,"googleAuthor":""},{"title":"Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib+ fulvestrant: results from MONALEESA-3","googleId":"47mR_Vw6Yl4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48711-5/abstract","googleCitationCount":11,"googleAuthor":"FJ Esteva"},{"title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","googleId":"aGs7bdOwwdwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31080-4/abstract","googleCitationCount":8,"googleAuthor":"C Abbosh"},{"title":"First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma","googleId":"y8LzN8HfCPcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35522-X/abstract","googleCitationCount":11,"googleAuthor":"S Turajlic"},{"title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B","googleId":"ZCyxD4-GM8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959161X","googleCitationCount":7,"googleAuthor":"RA Gafanov"},{"title":"Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"-tZuKFYzY_AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586987","googleCitationCount":5,"googleAuthor":"C Rolfo"},{"title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A","googleId":"1lFDicpHL2sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591621","googleCitationCount":5,"googleAuthor":"JMG Larkin"},{"title":"Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with …","googleId":"gai3XoXpTL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50407-0/abstract","googleCitationCount":11,"googleAuthor":"E Calvo"},{"title":"Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients","googleId":"bVK78XT20YIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583338","googleCitationCount":6,"googleAuthor":""},{"title":"Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the …","googleId":"wrGX6_M83lEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49922-5/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data","googleId":"d7EHdWetjYsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49080-7/abstract","googleCitationCount":9,"googleAuthor":"YK Kang"},{"title":"The immune profile of small HER2-positive breast cancers: A secondary analysis from the APT trial","googleId":"EVWrH3BmzFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311287","googleCitationCount":7,"googleAuthor":"R Barroso-Sousa"},{"title":"Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced …","googleId":"2VaILcEkmnwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602899","googleCitationCount":6,"googleAuthor":"RL Jones"},{"title":"Next-generation immunotherapies for lymphoma: one foot in the future","googleId":"9dkmkb6RV1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355243","googleCitationCount":11,"googleAuthor":""},{"title":"Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell …","googleId":"RkiRlFEsgJUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587555","googleCitationCount":5,"googleAuthor":"S Kim"},{"title":"Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics","googleId":"dpNkqauvhCoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31117-2/abstract","googleCitationCount":9,"googleAuthor":"H Hackl"},{"title":"Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed","googleId":"8VIe_zPSaEUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34204-8/abstract","googleCitationCount":9,"googleAuthor":"EC Smyth"},{"title":"Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head …","googleId":"qXp2ni0-4BcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49506-9/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced …","googleId":"DG3nr_4XfrsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49261-2/abstract","googleCitationCount":10,"googleAuthor":"N Agarwal"},{"title":"Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","googleId":"yLfzu97XHLAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350690","googleCitationCount":11,"googleAuthor":"LI Gordon"},{"title":"Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study","googleId":"aC4gGUBb4_cJ","googleLink":"https://vbn.aau.dk/ws/files/306929894/Six_cycles_of_R_CHOP_21_are_not_inferior_to_eight_cycles_for_treatment_of_diffuse_large_B_cell_lymphoma_A_Nordic_Lymphoma_Group_population_based_study.pdf","googleCitationCount":9,"googleAuthor":"JL Biccler"},{"title":"Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A …","googleId":"w0gnXY9HLy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60380-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder …","googleId":"2PulFdXf-o0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49584-7/abstract","googleCitationCount":10,"googleAuthor":"A Naing"},{"title":"Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results …","googleId":"95YtTGz5SEgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959665X","googleCitationCount":7,"googleAuthor":"S Peters"},{"title":"MEDIOLA: a phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours–new ovarian cancer …","googleId":"YLPWSpAo1kwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48914-X/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Quantitative lymph node burden as a 'very-high-risk'factor identifying head and neck cancer patients benefiting from postoperative chemoradiation","googleId":"Q1WS5orRUmcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309949","googleCitationCount":8,"googleAuthor":"ZS Zumsteg"},{"title":"Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials","googleId":"Z7lSCNBIwzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50283-6/abstract","googleCitationCount":8,"googleAuthor":"M Mau-Sorensen"},{"title":"Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis","googleId":"3j03RdQHacEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31245-1/abstract","googleCitationCount":7,"googleAuthor":"M Rota"},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"v-Niy_nMe2UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49084-4/abstract","googleCitationCount":12,"googleAuthor":"PR Galle"},{"title":"VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"2ewGa1j8zuAJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/veliagog-3005-integration-of-veliparib-with-front-line-chemothera","googleCitationCount":7,"googleAuthor":""},{"title":"Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)","googleId":"3UH3BEffnpMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49083-2/abstract","googleCitationCount":8,"googleAuthor":"TY Kim"},{"title":"Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast …","googleId":"K-dNdkkiFYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585817","googleCitationCount":5,"googleAuthor":"C Denkert"},{"title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","googleId":"dxWeF3qG5rUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32758-9/abstract","googleCitationCount":9,"googleAuthor":"K Homicsko"},{"title":"Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2 …","googleId":"EEfgpRzu7cUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959696X","googleCitationCount":6,"googleAuthor":"S Siena"},{"title":"Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: results …","googleId":"GW-Lz2YKnqcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50434-3/abstract","googleCitationCount":8,"googleAuthor":"JA Ledermann"},{"title":"Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer","googleId":"fZM3KUUnHG0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49027-3/abstract","googleCitationCount":9,"googleAuthor":"S Takahashi"},{"title":"CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"7awphYJB_DUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50422-7/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease","googleId":"Cd8LHiDHBBkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341389","googleCitationCount":10,"googleAuthor":"A Kamoun"},{"title":"Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L) 1","googleId":"Iv32EbsCZC8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49598-7/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results …","googleId":"YMmdJZltyYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593310","googleCitationCount":7,"googleAuthor":"D Rischin"},{"title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","googleId":"LiLrQuW9ZC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454677","googleCitationCount":10,"googleAuthor":"J Wang"},{"title":"Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second …","googleId":"EABTlbOmLvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589761","googleCitationCount":5,"googleAuthor":""},{"title":"A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL","googleId":"QE0S46-Aj7UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589669","googleCitationCount":7,"googleAuthor":"DJ Pinato"},{"title":"Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances","googleId":"cIUIuJvEg3UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30982-2/abstract","googleCitationCount":8,"googleAuthor":"T Valentin"},{"title":"Cancer mortality and predictions for 2018 in selected Australasian countries and Russia","googleId":"dvPl-t3kVGYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309937","googleCitationCount":5,"googleAuthor":"M Malvezzi"},{"title":"Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19)","googleId":"_LTLTO-_LPQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604527","googleCitationCount":5,"googleAuthor":"R Cornelissen"},{"title":"A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors","googleId":"_HQWIYeHDY8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49611-7/abstract","googleCitationCount":8,"googleAuthor":"CS Denlinger"},{"title":"Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)","googleId":"uG702wmLxQkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30282-0/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a …","googleId":"OoQCIphKtwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604278","googleCitationCount":5,"googleAuthor":""},{"title":"Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop","googleId":"Emp4rT3XMzQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31251-7/abstract","googleCitationCount":5,"googleAuthor":"AMM Eggermont"},{"title":"Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy","googleId":"1cOysXW6k6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50437-9/abstract","googleCitationCount":10,"googleAuthor":"H Mehanna"},{"title":"Phase I study of gefitinib (G)+ durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR …","googleId":"wj4LaT7SnicJ","googleLink":"https://mdanderson.elsevierpure.com/en/publications/phase-i-study-of-gefitinib-g-durvalumab-d-for-locally-advancedmet","googleCitationCount":6,"googleAuthor":"SW Kim"},{"title":"Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable mCRC","googleId":"MYOX_PG4AKsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30960-3/abstract","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma","googleId":"JmMefyRg44YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591840","googleCitationCount":4,"googleAuthor":"MM Regan"},{"title":"Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours","googleId":"8DHg7aJj4n4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594157","googleCitationCount":4,"googleAuthor":"C Massard"},{"title":"IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo)+ nab-paclitaxel (nab-P) vs placebo+ nab-P in treatment-naive …","googleId":"4GqWk8juhtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50399-4/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer","googleId":"Qn5RhGQtpkcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345478","googleCitationCount":9,"googleAuthor":""},{"title":"PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P)+ trastuzumab (T) with or without chemotherapy both followed by T-DM1 in …","googleId":"CqDBCIlOHewJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48709-7/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO …","googleId":"UV1SvNxckN4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341262","googleCitationCount":8,"googleAuthor":"E Fokas"},{"title":"Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an …","googleId":"5bgptQfyjK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345363","googleCitationCount":9,"googleAuthor":"I Bondarenko"},{"title":"Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","googleId":"46_DHhXzPr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590688","googleCitationCount":4,"googleAuthor":"ND James"},{"title":"Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma","googleId":"qfBg97Wo8Q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600323","googleCitationCount":4,"googleAuthor":"C Borg"},{"title":"A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma","googleId":"NBQeKINiMXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459899","googleCitationCount":4,"googleAuthor":""},{"title":"A multi-center phase IIA trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in …","googleId":"WxMK8lvpk1MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344781","googleCitationCount":5,"googleAuthor":"M Hidalgo"},{"title":"Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer","googleId":"CTBYx5KxG54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30991-3/abstract","googleCitationCount":8,"googleAuthor":"Y Wang"},{"title":"HER2: Defining a Neu target in non-small-cell lung cancer","googleId":"qxVMKBjHj2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31096-8/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"lpARJ9VcD0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960414X","googleCitationCount":5,"googleAuthor":"E Swisher"},{"title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","googleId":"fhEJJB4kmLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355218","googleCitationCount":9,"googleAuthor":""},{"title":"Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment","googleId":"kanofeyHxO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311135","googleCitationCount":5,"googleAuthor":""},{"title":"First report of AURORA, the Breast International Group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)","googleId":"6wd0BT809esJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30420-X/abstract","googleCitationCount":6,"googleAuthor":"F Hilbers"},{"title":"Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib","googleId":"Z7FK_hRE6tAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43119-0/abstract","googleCitationCount":7,"googleAuthor":"C Barone"},{"title":"Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy","googleId":"HqdEDhcKhH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350677","googleCitationCount":9,"googleAuthor":"P Boffetta"},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"xu0f8S430HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597125","googleCitationCount":6,"googleAuthor":"S Haas"},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"_VChNlQP92gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34063-3/abstract","googleCitationCount":10,"googleAuthor":"P Galle"},{"title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus …","googleId":"1GV9Brp-_yAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590998","googleCitationCount":5,"googleAuthor":"KN Chi"},{"title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus …","googleId":"1GV9Brp-_yAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590998","googleCitationCount":5,"googleAuthor":"KN Chi"},{"title":"Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial","googleId":"zM44t18gR_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49393-9/abstract","googleCitationCount":7,"googleAuthor":"IL Ray-Coquard"},{"title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","googleId":"7sVWQyyh4c0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43457-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"The landscape of NTRK fusions in Chinese patients with solid tumor","googleId":"sRlNzIBDgwoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48501-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Characterization of response to nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc) …","googleId":"e7iXe_XL5M0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49264-8/abstract","googleCitationCount":10,"googleAuthor":"BI Rini"},{"title":"Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on …","googleId":"IJmeWtf8n5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309895","googleCitationCount":6,"googleAuthor":"A Matikas"},{"title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy …","googleId":"9Lx0s8HabOQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30262-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the …","googleId":"_2RJZjMbiYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589700","googleCitationCount":4,"googleAuthor":""},{"title":"Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study","googleId":"22cY5a_u7iwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604291","googleCitationCount":4,"googleAuthor":""},{"title":"Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally …","googleId":"sgwxApH68sUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310786","googleCitationCount":6,"googleAuthor":"K Hutcheson"},{"title":"ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk'patients","googleId":"MiGZJQS89bAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341067","googleCitationCount":7,"googleAuthor":"M Hutchings"},{"title":"Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumour DNA","googleId":"mUSHNspINhkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589049","googleCitationCount":4,"googleAuthor":""},{"title":"Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer","googleId":"XZfS_yDtzlYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48878-9/abstract","googleCitationCount":9,"googleAuthor":"M Voskoboynik"},{"title":"Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic …","googleId":"pBA4_G-SPE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49507-0/abstract","googleCitationCount":8,"googleAuthor":"EEW Cohen"},{"title":"Exaggeration of PFS by blinded, independent, central review (BICR)","googleId":"OrG4tubPNTsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310269","googleCitationCount":6,"googleAuthor":"V Gebski"},{"title":"Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients …","googleId":"cOXfWgY_1T0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604229","googleCitationCount":4,"googleAuthor":""},{"title":"Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer","googleId":"s_qbrsj3-BQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355139","googleCitationCount":8,"googleAuthor":"F Khosrow-Khavar"},{"title":"Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE …","googleId":"ac0K3DdcUUcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589402","googleCitationCount":5,"googleAuthor":"A Naganuma"},{"title":"Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels","googleId":"97OmJZUbU38J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48557-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)","googleId":"Gg0zJkQzSaoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49288-0/abstract","googleCitationCount":8,"googleAuthor":"I Duran"},{"title":"Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular …","googleId":"NL7MyRiTDTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30530-7/abstract","googleCitationCount":5,"googleAuthor":"R Miksad"},{"title":"Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L) 1 targeting monoclonal antibodies","googleId":"rk7Uk4nTELAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30106-1/abstract","googleCitationCount":8,"googleAuthor":"LA Mauti"},{"title":"Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours","googleId":"fxCno9y9_nQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594364","googleCitationCount":3,"googleAuthor":""},{"title":"Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2","googleId":"OShqCjpI3AEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603777","googleCitationCount":5,"googleAuthor":"RC Doebele"},{"title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","googleId":"MqbuC3LLxu0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30535-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"-Gqh8RNS8v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604436","googleCitationCount":4,"googleAuthor":"N Peled"},{"title":"T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants","googleId":"rg4aRYHymYIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312050","googleCitationCount":4,"googleAuthor":"TP Mourikis"},{"title":"Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?","googleId":"ZzWJpOxPQq4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60974-9/abstract","googleCitationCount":4,"googleAuthor":"M Goebeler"},{"title":"Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells","googleId":"sy8X2EDvFd8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32102-7/abstract","googleCitationCount":9,"googleAuthor":"C Reduzzi"},{"title":"BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with …","googleId":"EoK116VmAIQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604151","googleCitationCount":5,"googleAuthor":"N Colombo"},{"title":"Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study","googleId":"Ke1NtfewcV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311639","googleCitationCount":8,"googleAuthor":""},{"title":"Methylation in cell-free DNA for early cancer detection","googleId":"qTUhgCxAneQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34910-5/abstract","googleCitationCount":11,"googleAuthor":"FF de la Cruz"},{"title":"Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)","googleId":"wbzaTQ0J9fIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34064-5/abstract","googleCitationCount":10,"googleAuthor":"K Shitara"},{"title":"Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting …","googleId":"-dvwUuBFYzkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49104-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): characterization of hepatic adverse reactions (ARs)","googleId":"qsIQCAhT4lwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603182","googleCitationCount":3,"googleAuthor":"H Gelderblom"},{"title":"Phase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination …","googleId":"PknI-lUseN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590640","googleCitationCount":4,"googleAuthor":"JN Graff"},{"title":"Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small …","googleId":"ofX1tZ97urAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580383","googleCitationCount":3,"googleAuthor":"V Subbiah"},{"title":"CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed …","googleId":"KbMqFzUSgjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586471","googleCitationCount":4,"googleAuthor":"I Compter"},{"title":"Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from> 165,000 pan-solid tumours","googleId":"c1ST_xKjQ24J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586653","googleCitationCount":4,"googleAuthor":""},{"title":"Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC","googleId":"reiw4tDd1lQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45491-4/abstract","googleCitationCount":8,"googleAuthor":"IV Bempt"},{"title":"Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors","googleId":"_NHHrFpPaNcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50440-9/abstract","googleCitationCount":7,"googleAuthor":"IM Rodas"},{"title":"Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis","googleId":"bvqTgtGDQVIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583211","googleCitationCount":3,"googleAuthor":""},{"title":"Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial","googleId":"ksZUTftglUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589712","googleCitationCount":5,"googleAuthor":""},{"title":"On the right TRK: from oncogene discovery to cancer therapeutics","googleId":"KewhpccVYiYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)55115-8/abstract","googleCitationCount":3,"googleAuthor":"M Barbacid"},{"title":"Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"pkplFhe9OFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49325-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)","googleId":"moTCul8Dd6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30118-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or …","googleId":"3EFTLs8XT2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591281","googleCitationCount":3,"googleAuthor":"TK Choueiri"},{"title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","googleId":"YQuQ0fI90WUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594388","googleCitationCount":5,"googleAuthor":""},{"title":"Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?","googleId":"MZjlnOnzhZQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31212-8/abstract","googleCitationCount":4,"googleAuthor":"N Paragios"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer …","googleId":"exBE5CKpzxsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43120-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with …","googleId":"E6Vk8Gjv91YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593462","googleCitationCount":4,"googleAuthor":""},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"hByNxCw893MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43057-3/abstract","googleCitationCount":6,"googleAuthor":"DSW Tan"},{"title":"Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations","googleId":"FFHoMYpLHiQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49793-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (PTS) with …","googleId":"ILa2QrTyCNYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49701-9/abstract","googleCitationCount":7,"googleAuthor":"H Gogas"},{"title":"Improved survival in metastatic germ-cell cancer","googleId":"WoZ4C1ZU4N0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350574","googleCitationCount":8,"googleAuthor":"J Beyer"},{"title":"Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core …","googleId":"-X1aZfiz550J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584034","googleCitationCount":4,"googleAuthor":"M Reinisch"},{"title":"Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus …","googleId":"1N9RO0A0CC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311688","googleCitationCount":10,"googleAuthor":""},{"title":"A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC …","googleId":"Axnebzzsj1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49405-2/abstract","googleCitationCount":7,"googleAuthor":"RE O'Cearbhaill"},{"title":"Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project","googleId":"L1EumcapPtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349877","googleCitationCount":9,"googleAuthor":"U Dafni"},{"title":"Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer …","googleId":"fSY7723lzXIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590652","googleCitationCount":5,"googleAuthor":"JR Osborne"},{"title":"Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer","googleId":"hW8cYuGDlp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960089X","googleCitationCount":3,"googleAuthor":"A Arias"},{"title":"Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)","googleId":"yo2UfzeWQ9QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49164-3/abstract","googleCitationCount":7,"googleAuthor":"T Meyer"},{"title":"Dissociated responses in patients with metastatic solid tumours treated with immunotherapy","googleId":"frcdHFz2Zz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594935","googleCitationCount":4,"googleAuthor":"X Paoletti"},{"title":"Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)","googleId":"yJASw6h6rkIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596673","googleCitationCount":4,"googleAuthor":"J Naidoo"},{"title":"Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with …","googleId":"12CcdXNKCfcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49396-4/abstract","googleCitationCount":7,"googleAuthor":"V Moreno"},{"title":"High eosinophils lymphocyte ratio (ELR) related with subtype of breast cancer in Sanglah General Hospital, Bali","googleId":"oaHWuhNvDssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43014-7/abstract","googleCitationCount":6,"googleAuthor":"AAW Lestari"},{"title":"Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing","googleId":"DGLcXY6_vVIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34242-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"TiNivo: tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): final results","googleId":"IN2ZAma8EnMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591608","googleCitationCount":4,"googleAuthor":"S Negrier"},{"title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study …","googleId":"qggBJD9a4wwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312852","googleCitationCount":5,"googleAuthor":""},{"title":"High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study","googleId":"3e62PtuMWVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594820","googleCitationCount":3,"googleAuthor":"JY Blay"},{"title":"Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study","googleId":"4RgfXXB91GsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344343","googleCitationCount":3,"googleAuthor":"A Cortellini"},{"title":"Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)","googleId":"wa-NvtqVoAgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30018-3/abstract","googleCitationCount":8,"googleAuthor":"A Hollebecque"},{"title":"Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (PTS)","googleId":"mp9K3_U8oL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49271-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Efficacy and safety of first-line durvalumab (D)±tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m …","googleId":"b8LcIsIcr9wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30261-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Therapeutic drug monitoring of oral anticancer drugs-preliminary results of a prospective study","googleId":"W5k8d2UdlDQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586641","googleCitationCount":3,"googleAuthor":""},{"title":"A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer …","googleId":"x9yg4o0qsQ4J","googleLink":"https://www.researchgate.net/profile/Arun_Azad/publication/328455745_792OA_randomized_phase_II_study_of_cabazitaxel_CAB_vs_ABI_abiraterone_or_ENZ_enzalutamide_in_poor_prognosis_metastatic_castration-resistant_prostate_cancer_mCRPC/links/5bdad964299bf1124fb20b99/792OA-randomized-phase-II-study-of-cabazitaxel-CAB-vs-ABI-abiraterone-or-ENZ-enzalutamide-in-poor-prognosis-metastatic-castration-resistant-prostate-cancer-mCRPC.pdf","googleCitationCount":7,"googleAuthor":"KN Chi"},{"title":"Patients and physicians' satisfaction with telemedicine (TM) in cancer care and factors that correlate with a positive patient's experience","googleId":"n5PdAVekb4sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599239","googleCitationCount":4,"googleAuthor":"T Abbas"},{"title":"ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)","googleId":"AOWi8m4UCv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30515-0/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma …","googleId":"HLmNZ2rYVtwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341955116X","googleCitationCount":5,"googleAuthor":""},{"title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation …","googleId":"2KintmRMi6cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50432-X/abstract","googleCitationCount":7,"googleAuthor":"N Colombo"},{"title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","googleId":"N-DJLkVNhUMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35046-X/abstract","googleCitationCount":10,"googleAuthor":"JM Michot"},{"title":"CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A …","googleId":"hVhx1z_lOTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50449-5/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors","googleId":"wZRwMlqwP8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34141-9/abstract","googleCitationCount":7,"googleAuthor":"LM Sholl"},{"title":"Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell …","googleId":"uPWZfFwn83gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593991","googleCitationCount":4,"googleAuthor":"V Makker"},{"title":"Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) …","googleId":"k0CL5401In0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49258-2/abstract","googleCitationCount":6,"googleAuthor":"G Couchy"},{"title":"IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone …","googleId":"xi2eNKKHCE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602917","googleCitationCount":3,"googleAuthor":""},{"title":"Analysis of tumour samples from SOLO1: frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to …","googleId":"KkrDcw230UEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592110","googleCitationCount":3,"googleAuthor":"C Gourley"},{"title":"Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours","googleId":"uZZBBqJgbtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43045-7/abstract","googleCitationCount":6,"googleAuthor":"V Subbiah"},{"title":"Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a …","googleId":"AMOF66wjPykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591372","googleCitationCount":3,"googleAuthor":""},{"title":"Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression","googleId":"zxDOEt4tFjwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49513-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a …","googleId":"QFDL9MeZUX4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49218-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"iMyptmkb4qAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43458-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer …","googleId":"oWQibnv50MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590925","googleCitationCount":3,"googleAuthor":"E Castro"},{"title":"A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)","googleId":"SBoGx6_4TE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49219-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?","googleId":"tTPSvydvdLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609683","googleCitationCount":4,"googleAuthor":""},{"title":"Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and …","googleId":"MhlCcH1Dj0cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30058-4/abstract","googleCitationCount":5,"googleAuthor":"A Drilon"},{"title":"A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)","googleId":"202ljc2qi_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49590-2/abstract","googleCitationCount":6,"googleAuthor":"M Hidalgo"},{"title":"Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: long-term outcomes of the INSIGHT study","googleId":"SHUxNIw4yZ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581236","googleCitationCount":3,"googleAuthor":"DW Kim"},{"title":"Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1","googleId":"8H7rRIsg6pwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594212","googleCitationCount":5,"googleAuthor":"S Gupta"},{"title":"A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous …","googleId":"GHZFoxBDHvgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597721","googleCitationCount":3,"googleAuthor":"I Bondarenko"},{"title":"A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous …","googleId":"GHZFoxBDHvgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597721","googleCitationCount":3,"googleAuthor":"I Bondarenko"},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort)(NCT02601950)","googleId":"uIQHn2fE7OcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50077-1/abstract","googleCitationCount":6,"googleAuthor":"RL Jones"},{"title":"Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8","googleId":"zsV_I6ViyJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48486-X/abstract","googleCitationCount":9,"googleAuthor":"P Laurent-Puig"},{"title":"Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer","googleId":"a0838eudHKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593334","googleCitationCount":4,"googleAuthor":"V Noronha"},{"title":"Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the use via expanded access to brigatinib (UVEA-Brig) study","googleId":"VVgT55uDczAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597526","googleCitationCount":3,"googleAuthor":""},{"title":"Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): a planned interim analysis","googleId":"7HM5X7gZd8QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48961-8/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: pooled analysis of the OAK and POPLAR trials","googleId":"ypuHZ3N8lJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32664-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on …","googleId":"_tkom3OgKyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599719","googleCitationCount":3,"googleAuthor":"G Zalcman"},{"title":"The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation","googleId":"AlKpG67mLt0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35517-6/abstract","googleCitationCount":8,"googleAuthor":"V Prasad"},{"title":"Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) …","googleId":"dYyiaYjvhP0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959322X","googleCitationCount":3,"googleAuthor":"J Guigay"},{"title":"Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase …","googleId":"jA5w4dxJwEUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310221","googleCitationCount":5,"googleAuthor":"D Schadendorf"},{"title":"Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse …","googleId":"AGT8yDUzRAwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454793","googleCitationCount":5,"googleAuthor":"E Ollier"},{"title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic …","googleId":"1pcTlI0Rld8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591360","googleCitationCount":7,"googleAuthor":""},{"title":"Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis","googleId":"Djaa9aJh6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34561-2/abstract","googleCitationCount":7,"googleAuthor":"H Uno"},{"title":"Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment","googleId":"lIDini_Z_jQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31120-2/abstract","googleCitationCount":6,"googleAuthor":"F Conforti"},{"title":"Divining responder populations from survival data","googleId":"DxPLrBUZ-2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311962","googleCitationCount":4,"googleAuthor":"S Ventz"},{"title":"Applicability of the Lung Immune Prognostic Index (LIPI) in patients with metastatic solid tumors when treated with Immune Checkpoint Inhibitors (ICI) in early clinical …","googleId":"PvfSsvT5LKYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30013-4/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3)","googleId":"-sGV04b9ZXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310828","googleCitationCount":3,"googleAuthor":"H Zuo"},{"title":"Update on the phase II SUMMIT trial: Neratinib+ fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer","googleId":"mFPiGnNqjqkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30302-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"C4yv7hcD0rYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582126","googleCitationCount":3,"googleAuthor":"SK Sandhu"},{"title":"Pharmacokinetics (PK), safety, and efficacy of trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced …","googleId":"xuL_iwInvN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585520","googleCitationCount":3,"googleAuthor":""},{"title":"Updated results of M7824 (MSB0011359C): a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC","googleId":"xtOf0Fm0HWIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49875-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)","googleId":"B_B8s3LvPd0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597885","googleCitationCount":4,"googleAuthor":"AB Bourla"},{"title":"CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence …","googleId":"zwg2g7sIzhkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49244-2/abstract","googleCitationCount":5,"googleAuthor":"M Akce"},{"title":"Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup …","googleId":"UKhFf-qiTuUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579431","googleCitationCount":3,"googleAuthor":"MC Wang"},{"title":"NCI-MATCH arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (Mut/del) or PTEN protein …","googleId":"WKJaqQzaQlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48885-6/abstract","googleCitationCount":6,"googleAuthor":"O Jegede"},{"title":"Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies","googleId":"Faa6rKSZe2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49122-9/abstract","googleCitationCount":7,"googleAuthor":"SJ Klempner"},{"title":"Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer","googleId":"4h7XLnw8nw0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344872","googleCitationCount":2,"googleAuthor":"I Marquez-Rodas"},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"3ydErE3j5G4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344446","googleCitationCount":3,"googleAuthor":""},{"title":"TRIBE2: A phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)","googleId":"VStRIiT5upgJ","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/328503649_LBA20TRIBE2_A_phase_III_randomized_strategy_study_by_GONO_in_the_1st-_and_2nd-line_treatment_of_unresectable_metastatic_colorectal_cancer_mCRC_patients_pts/links/5dd2cbc04585156b351e8234/LBA20TRIBE2-A-phase-III-randomized-strategy-study-by-GONO-in-the-1st-and-2nd-line-treatment-of-unresectable-metastatic-colorectal-cancer-mCRC-patients-pts.pdf","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients","googleId":"zdZdSBVbaGQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48898-4/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Not only tumor but also therapy heterogeneity","googleId":"yPEyYUtkJRMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34999-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials","googleId":"leJr73uXJtkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48725-5/abstract","googleCitationCount":6,"googleAuthor":"M Elmeliegy"},{"title":"Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor","googleId":"CsokYC2ZV6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34197-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","googleId":"HNYnz896378J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50392-1/abstract","googleCitationCount":6,"googleAuthor":"C Hulme"},{"title":"FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting …","googleId":"T3_2w3N17WAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587890","googleCitationCount":3,"googleAuthor":""},{"title":"Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study","googleId":"R5-UvHVZPAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589670","googleCitationCount":3,"googleAuthor":""},{"title":"IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo)+ …","googleId":"dP8XbDbw4OwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30152-8/abstract","googleCitationCount":5,"googleAuthor":"S Peters"},{"title":"100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice","googleId":"pd3owMfB99AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619010","googleCitationCount":2,"googleAuthor":"J Mitchell"},{"title":"30 months relapse-free survival, overall survival, and long-term toxicity update of (neo) adjuvant ipilimumab (ipi)+ nivolumab (nivo) in macroscopic stage III melanoma …","googleId":"uVN0BgNONXAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32759-0/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Pleural mesothelioma: is the surgeon still there?","googleId":"QHIGoicQKRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934116X","googleCitationCount":6,"googleAuthor":"I Opitz"},{"title":"Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients","googleId":"D5iOGmfxCc4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30353-9/abstract","googleCitationCount":4,"googleAuthor":"M Keyaerts"},{"title":"The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case–control and Mendelian randomization study in the European …","googleId":"dfJBOzJqmk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312098","googleCitationCount":4,"googleAuthor":"KS Byrne"},{"title":"Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD …","googleId":"I-4f5XrMMysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595679","googleCitationCount":2,"googleAuthor":"SK Sandhu"},{"title":"A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer","googleId":"0kEXAVRxX1kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350057","googleCitationCount":8,"googleAuthor":"A Hapfelmeier"},{"title":"Oral bisphosphonate use and lung cancer incidence among postmenopausal women","googleId":"azihxASBIVIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348914","googleCitationCount":5,"googleAuthor":"JL Freudenheim"},{"title":"Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a …","googleId":"JsffEb0BREgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599744","googleCitationCount":4,"googleAuthor":""},{"title":"A novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","googleId":"qBPIrrCb_7AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419601468","googleCitationCount":3,"googleAuthor":""},{"title":"Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability","googleId":"F9gE0H5vyFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50279-4/abstract","googleCitationCount":5,"googleAuthor":"J Martin-Liberal"},{"title":"Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder …","googleId":"iYGyAXl2PrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591219","googleCitationCount":5,"googleAuthor":"A Briganti"},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"1b8-qnsI4g8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48947-3/abstract","googleCitationCount":6,"googleAuthor":"E Shinozaki"},{"title":"Passion for immune checkpoint blockade in triple negative breast cancer: comment on the IMpassion130 study","googleId":"kBjNBT-v-bEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30988-3/abstract","googleCitationCount":6,"googleAuthor":"S Loi"},{"title":"Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication","googleId":"Aiy0S5jwlmkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341948","googleCitationCount":7,"googleAuthor":"L Xie"},{"title":"Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database","googleId":"fr0HUE5jnSwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344628","googleCitationCount":2,"googleAuthor":"MD Gomez"},{"title":"Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG …","googleId":"DDv6qX5H1fMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30376-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","googleId":"vbexyfXAgH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586720","googleCitationCount":5,"googleAuthor":"M Dillon"},{"title":"Durvalumab+ monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)","googleId":"Bjk8T9XWrfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594133","googleCitationCount":3,"googleAuthor":"M Cho"},{"title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","googleId":"MM784Tc0Lj8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586604","googleCitationCount":6,"googleAuthor":"LL Siu"},{"title":"PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy","googleId":"PrZYxMYAA_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30186-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell …","googleId":"79wZyRWvoQEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454665","googleCitationCount":7,"googleAuthor":"MJ Awan"},{"title":"Comparison of immuno-oncology (IO) biomarkers in adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder …","googleId":"C-1XEyHC5q0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591463","googleCitationCount":3,"googleAuthor":"AB Schrock"},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of …","googleId":"oQppqByNKqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585465","googleCitationCount":3,"googleAuthor":"F André"},{"title":"Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II","googleId":"z2E74tiDVPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350471","googleCitationCount":13,"googleAuthor":"I Sestak"},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting","googleId":"WulZALHnYxgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30992-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial","googleId":"J8alWGTBcEQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49798-6/abstract","googleCitationCount":6,"googleAuthor":"S Peters"},{"title":"Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology","googleId":"v_dRr6l4kF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583363","googleCitationCount":2,"googleAuthor":""},{"title":"Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer","googleId":"rWHYVw3pLmIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35520-6/abstract","googleCitationCount":7,"googleAuthor":"C Abbosh"},{"title":"BRCA1/2 testing in HER2-advanced breast cancer (ABC): Results from the European component of a multi-country real-world study","googleId":"qbeJhOLnt5MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585143","googleCitationCount":3,"googleAuthor":""},{"title":"NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option","googleId":"ZYYytu1qVxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30807-5/abstract","googleCitationCount":3,"googleAuthor":"B Weinberg"},{"title":"Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours","googleId":"DZin-WFLbh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586690","googleCitationCount":3,"googleAuthor":"AR Parikh"},{"title":"Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced …","googleId":"CcVG-7Wo73wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49819-0/abstract","googleCitationCount":5,"googleAuthor":"L Mezquita"},{"title":"Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer …","googleId":"XrBCZADY8pYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585659","googleCitationCount":2,"googleAuthor":""},{"title":"Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma","googleId":"4QZ2XKqg88EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49160-6/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours","googleId":"y8iEV3ILn1oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590585","googleCitationCount":3,"googleAuthor":"A Drilon"},{"title":"Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?","googleId":"AQk2kGntoj0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325886","googleCitationCount":4,"googleAuthor":""},{"title":"Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)","googleId":"LbLRR1QH8ssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50329-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)","googleId":"gtkC0EYeKYIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30417-X/abstract","googleCitationCount":4,"googleAuthor":"A Lusque"},{"title":"New designs in early clinical drug development","googleId":"FfIjyVlSDqMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945984X","googleCitationCount":2,"googleAuthor":"A Mansinho"},{"title":"Cancer stigma related to beliefs of patients and care providers","googleId":"qEQMHjtaC9IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49997-3/abstract","googleCitationCount":5,"googleAuthor":"H Malhotra"},{"title":"Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy","googleId":"tuUrEWciQPIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584010","googleCitationCount":3,"googleAuthor":"G Bataillon"},{"title":"Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)","googleId":"IixMObcX2doJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49159-X/abstract","googleCitationCount":5,"googleAuthor":"C Barone"},{"title":"Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany","googleId":"7MAhmurffwgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49861-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland","googleId":"WZAmoDRAzPkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595539","googleCitationCount":2,"googleAuthor":"C Hoeller"},{"title":"Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study …","googleId":"27Fs3gJtFJsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48911-4/abstract","googleCitationCount":6,"googleAuthor":"A Krämer"},{"title":"Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma …","googleId":"0h-UvuzlqlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50448-3/abstract","googleCitationCount":6,"googleAuthor":"N Meyer"},{"title":"Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial","googleId":"SW9v8XEooG4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595412","googleCitationCount":2,"googleAuthor":"M Kurt"},{"title":"Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?","googleId":"zVN3XqkU3XgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34553-3/abstract","googleCitationCount":6,"googleAuthor":"LA Diaz"},{"title":"Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced …","googleId":"77WKt7vB2NQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594182","googleCitationCount":2,"googleAuthor":""},{"title":"Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients","googleId":"KYiN-WlIBF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596946","googleCitationCount":2,"googleAuthor":"JM Janssen"},{"title":"Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic …","googleId":"3qpqT2NenAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586628","googleCitationCount":6,"googleAuthor":"A Naing"},{"title":"Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid …","googleId":"D8Qm5dbghikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586860","googleCitationCount":2,"googleAuthor":"J Evans"},{"title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence …","googleId":"rPMFejUfIfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30705-7/abstract","googleCitationCount":3,"googleAuthor":"J Knox"},{"title":"Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting","googleId":"tGhrxE_2C8kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596958","googleCitationCount":2,"googleAuthor":""},{"title":"Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes","googleId":"m7demNaXHzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32604-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7. 1) in a …","googleId":"afD_1o2WMEkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589414","googleCitationCount":3,"googleAuthor":"S Kasper"},{"title":"WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)","googleId":"02qI_6dBvKAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959617X","googleCitationCount":2,"googleAuthor":"L Bosch"},{"title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma …","googleId":"dB6_QWc55DAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49263-6/abstract","googleCitationCount":6,"googleAuthor":"BI Rini"},{"title":"Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated …","googleId":"hgOrPzbIFEIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586744","googleCitationCount":2,"googleAuthor":"M Voskoboynik"},{"title":"Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma","googleId":"7b7f52cXm1IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34554-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Phase I Clinical Study for Validation of Fimaporfin-Based Photochemical Internalisation: A Novel Technology for Enhancing Cellular Immune Responses …","googleId":"qA9jNlWbkyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344963","googleCitationCount":2,"googleAuthor":""},{"title":"Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)","googleId":"ffZwBxGmT6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960428X","googleCitationCount":2,"googleAuthor":"H Jespersen"},{"title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","googleId":"Dx12fVzxsFoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600967","googleCitationCount":3,"googleAuthor":"K Tolba"},{"title":"Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced …","googleId":"2S3PhaN0jG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49165-5/abstract","googleCitationCount":5,"googleAuthor":"T Yau"},{"title":"Phase I combination dose-finding/phase II expansion cohorts of lenvatinib+ etoposide+ ifosfamide in patients (pts) aged 2 to≤ 25 years with relapsed …","googleId":"dNKjQ3iilMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960298X","googleCitationCount":2,"googleAuthor":"R Venkatramani"},{"title":"Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)","googleId":"YI_MIgnKgNYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591062","googleCitationCount":2,"googleAuthor":""},{"title":"Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer","googleId":"upXe_EbA6AwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49862-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of …","googleId":"SnMi6rDf79wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49192-8/abstract","googleCitationCount":5,"googleAuthor":"S Nomura"},{"title":"Genomic medicine France 2025","googleId":"RDbuA1CJBJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45473-2/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients …","googleId":"lcZoy9TOIo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604540","googleCitationCount":4,"googleAuthor":"L Mileshkin"},{"title":"Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal …","googleId":"9D9lBdM51P4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587567","googleCitationCount":4,"googleAuthor":"J Webster"},{"title":"The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an …","googleId":"ElEXkI3qIx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30802-6/abstract","googleCitationCount":4,"googleAuthor":"J Riedl"},{"title":"Analytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer","googleId":"8_GW3SVfrIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48482-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer","googleId":"SUE2pIt70EsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584666","googleCitationCount":2,"googleAuthor":""},{"title":"Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad …","googleId":"NErDi8rtr6cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959336X","googleCitationCount":2,"googleAuthor":"M Eckstein"},{"title":"Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments","googleId":"D8yiNVBk3bsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58092-9/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Safety and efficacy of the oral CXCR4 inhibitor X4P-001+ axitinib in advanced renal cell carcinoma patients: an analysis of subgroup responses by prior …","googleId":"Y1Ehd4Qtk8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959398X","googleCitationCount":2,"googleAuthor":""},{"title":"Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma","googleId":"ys_QIPbDK_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34198-5/abstract","googleCitationCount":6,"googleAuthor":"A Santambrogio"},{"title":"Gastric cancer in young Latin women: bad prognostic factors and outcomes","googleId":"B9eRc92XZUYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30664-7/abstract","googleCitationCount":4,"googleAuthor":"M Herrera"},{"title":"Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous …","googleId":"HRQjPB3zpxYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597289","googleCitationCount":2,"googleAuthor":"G Metro"},{"title":"Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): preliminary results from the phase IIIb, international, open-label …","googleId":"86URG_FAnVgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33699-3/abstract","googleCitationCount":6,"googleAuthor":"A Falcone"},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"FlutAU2M_2oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62207-6/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune …","googleId":"24OcWWMgBTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30115-2/abstract","googleCitationCount":5,"googleAuthor":"K Rounis"},{"title":"An international randomized cross-over bio-equivalence study of oral paclitaxel+ HM30181 compared with weekly intravenous (IV) paclitaxel in patients with …","googleId":"tVq3UvRtUpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586999","googleCitationCount":2,"googleAuthor":"C Jackson"},{"title":"Revisiting surveillance schemes for cancer survivors","googleId":"mIWaWB4rZ44J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31201-3/abstract","googleCitationCount":3,"googleAuthor":"Ø Holme"},{"title":"Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma","googleId":"uigtFEVq2q4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312748","googleCitationCount":4,"googleAuthor":""},{"title":"SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","googleId":"D1-ZHc_ZHFgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604308","googleCitationCount":2,"googleAuthor":"S Danson"},{"title":"Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study","googleId":"7eINOEgSKLwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48476-7/abstract","googleCitationCount":5,"googleAuthor":"MC Liu"},{"title":"NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours","googleId":"Jt8-Npq6L1gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594418","googleCitationCount":2,"googleAuthor":""},{"title":"RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients","googleId":"ZanpkEJT3NcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35523-1/abstract","googleCitationCount":5,"googleAuthor":"P Carmeliet"},{"title":"Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours","googleId":"RJhAO-HorzcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591992","googleCitationCount":2,"googleAuthor":"MA Habra"},{"title":"Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in …","googleId":"hEOyUqqtvVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619587","googleCitationCount":2,"googleAuthor":""},{"title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC) …","googleId":"1Aijnu-5Ks0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49409-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Atezolizumab+ bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150","googleId":"MDhk9wDWOy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49243-0/abstract","googleCitationCount":7,"googleAuthor":"MP Ducreux"},{"title":"A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort …","googleId":"1obQciRoQDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593218","googleCitationCount":3,"googleAuthor":""},{"title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","googleId":"gJE29fDVmmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344148","googleCitationCount":2,"googleAuthor":"E McGowan"},{"title":"Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D","googleId":"kEnW5m7b9aMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588287","googleCitationCount":2,"googleAuthor":"M Fakih"},{"title":"Harmonization study of tumour mutational burden determination in non-small cell lung cancer (NSCLC)","googleId":"LWzbjhWKsyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603625","googleCitationCount":2,"googleAuthor":""},{"title":"Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial","googleId":"67N87ZRmiaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459863","googleCitationCount":3,"googleAuthor":"EM Holmes"},{"title":"Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB …","googleId":"ZRds5-27lJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50273-3/abstract","googleCitationCount":6,"googleAuthor":"A Puccini"},{"title":"Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial","googleId":"67N87ZRmiaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459863","googleCitationCount":3,"googleAuthor":"EM Holmes"},{"title":"Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB …","googleId":"ZRds5-27lJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50273-3/abstract","googleCitationCount":6,"googleAuthor":"A Puccini"},{"title":"A Phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)","googleId":"_qT-tXoBBbIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30957-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers","googleId":"LfnoKY2R69kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588901","googleCitationCount":2,"googleAuthor":""},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary …","googleId":"CILzF8eBg4QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49105-9/abstract","googleCitationCount":5,"googleAuthor":"A Khattak"},{"title":"A Phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy","googleId":"e7SVTZpTMk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590160","googleCitationCount":2,"googleAuthor":""},{"title":"Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in …","googleId":"pyKjmBDf3xgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343969","googleCitationCount":2,"googleAuthor":""},{"title":"Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?","googleId":"NB8Hi1GuwtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31250-5/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"ad5a_MrcssIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582217","googleCitationCount":3,"googleAuthor":""},{"title":"Phase i/ii study with cxcl12 inhibitor nox-a12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer","googleId":"f1NLCQtfecsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588330","googleCitationCount":2,"googleAuthor":""},{"title":"Kinase fusions in colorectal cancers: a unique biologic subset","googleId":"WUq5GpjCnUkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48923-0/abstract","googleCitationCount":6,"googleAuthor":"F Pietrantonio"},{"title":"Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)","googleId":"CqE-zjVeDAMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50464-1/abstract","googleCitationCount":6,"googleAuthor":"DS Tan"},{"title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer …","googleId":"NtLBNKXgZ6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30955-X/abstract","googleCitationCount":3,"googleAuthor":"P Hammel"},{"title":"Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 …","googleId":"2kUiw_nlLiYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594327","googleCitationCount":2,"googleAuthor":"JJ Luke"},{"title":"Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet","googleId":"GNc_h7abBzgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35001-X/abstract","googleCitationCount":6,"googleAuthor":"AJ Armstrong"},{"title":"Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients …","googleId":"jYGxuKR16nsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603789","googleCitationCount":2,"googleAuthor":"P Bono"},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"4xLbTARyipwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582114","googleCitationCount":2,"googleAuthor":""},{"title":"Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small …","googleId":"Lo2Empmm3LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034463X","googleCitationCount":2,"googleAuthor":"C Jacob"},{"title":"Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma …","googleId":"jt_ciYIBIWcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593279","googleCitationCount":2,"googleAuthor":"E Cohen"},{"title":"Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer","googleId":"e4WPTloFnGUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30650-7/abstract","googleCitationCount":4,"googleAuthor":"C Kim"},{"title":"Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen+/-gonadotropin …","googleId":"PB265SW4nzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50398-2/abstract","googleCitationCount":4,"googleAuthor":"M Reinisch"},{"title":"A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell …","googleId":"7DB2nfYUFLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593528","googleCitationCount":2,"googleAuthor":"MC Merlano"},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)","googleId":"JXEhguGzaDsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50080-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L) 1 inhibitors (IO …","googleId":"miDYMwHljw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49828-1/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444","googleId":"95qOOxbOaIAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49594-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours","googleId":"NBUe0qPYAdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586781","googleCitationCount":2,"googleAuthor":""},{"title":"Phase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)","googleId":"v3vmDg4a2jQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585684","googleCitationCount":2,"googleAuthor":""},{"title":"Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)","googleId":"Td8b0INfsyQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48879-0/abstract","googleCitationCount":7,"googleAuthor":"M Mau-Sorensen"},{"title":"PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","googleId":"QY7AZBRV7b8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582035","googleCitationCount":2,"googleAuthor":""},{"title":"Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a …","googleId":"4siBliACusoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588925","googleCitationCount":2,"googleAuthor":"S Cascinu"},{"title":"Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC)","googleId":"P67rOlN-3LUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49508-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple …","googleId":"D2YnAkBP9dEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30276-5/abstract","googleCitationCount":4,"googleAuthor":"S Loi"},{"title":"Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients","googleId":"gm6dYt9myO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589360","googleCitationCount":3,"googleAuthor":""},{"title":"Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?","googleId":"QQz17_d7Vb0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350483","googleCitationCount":8,"googleAuthor":"ID Davis"},{"title":"Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)","googleId":"wTtQBxEakAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599343","googleCitationCount":2,"googleAuthor":""},{"title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort","googleId":"F8wS8Ce7ag0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49599-9/abstract","googleCitationCount":4,"googleAuthor":"J Mazieres"},{"title":"Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study","googleId":"tXHXunOKD9AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621745","googleCitationCount":3,"googleAuthor":"J Mazieres"},{"title":"Platelet Lymphocyte Ratio (PLR) Related with Clinicopathological Characteristics of Balinese Women Breast Cancer Patient","googleId":"cmSZPWL1sAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419623732","googleCitationCount":4,"googleAuthor":"S Wiranata"}]